Farmer R, Burbano SD, Patel NS, Sarmiento A, Smith AJ and Kelly MP (2020) Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. *Cellular signalling* **70**:109592.

Faropoulos K, Tsolaki V, Georgakopoulou VE, Trakas I, Tarantinos K, Papalexis P, Spandidos DA, Aravantinou-Fatorou A, Mathioudakis N, Trakas N, Lavdas E and Fotakopoulos G (2023) Value of sildenafil treatment for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction following aneurysmal subarachnoid hemorrhage. *Med Int (Lond)* **3**:19.

Faucz FR, Horvath A, Rothenbuhler A, Almeida MQ, Libe R, Raffin-Sanson ML, Bertherat J, Carraro DM, Soares FA, Molina Gde C, Campos AH, Alexandre RB, Bendhack ML, Nesterova M and Stratakis CA (2011) Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. *The Journal of clinical endocrinology and metabolism* **96**:E135-140.

Favot L, Keravis T and Lugnier C (2004) Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. *Thromb Haemost* **92**:634-645.

Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA and Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. *Proc Natl Acad Sci U S A* **97**:3702-3707.

Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A, Pearl HD and collaborators Ls (2020) PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. *Movement disorders : official journal of the Movement Disorder Society* **35**:606-615.

Feinstein WP, Zhu B, Leavesley SJ, Sayner SL and Rich TC (2012) Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells. *Am J Physiol Cell Physiol* **302**:C839-852.

Feng H, Wang C, He W, Wu X, Li S, Zeng Z, Wei M and He B (2019) Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. *Metabolic brain disease* **34**:583-591.

Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ and Vilardaga JP (2009) Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. *Nat Chem Biol* **5**:734-742.

Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C and Aarsland D (2017) The psychosis spectrum in Parkinson disease. *Nature reviews Neurology* **13**:81-95.

Fioni A, Selg E, Cenacchi V, Acevedo F, Brogin G, Gerde P and Puccini P (2018) Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the Preciselnhale Technology. *J Aerosol Med Pulm Drug Deliv* **31**:61-70.

Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, Rao S, Thakkar DM, Deng SX, Landry DW and Arancio O (2013) Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. *European journal of medicinal chemistry* **60**:285-294.

Fisher DA, Smith JF, Pillar JS, St Denis SH and Cheng JB (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. *J Biol Chem* **273**:15559-15564.

Flacke JP, Flacke H, Appukuttan A, Palisaar RJ, Noldus J, Robinson BD, Reusch HP, Zippin JH and Ladilov Y (2013) Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells. *J Biol Chem* **288**:3126-3135.

Forestá C, De Toni L, Di Mambro A, Garolla A, Ferlin A and Zuccarello D (2009) The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. *J Sex Med* **6**:369-372.

Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE and Mitchell MI (2006) Tadalafil pharmacokinetics in healthy subjects. *Br J Clin Pharmacol* **61**:280-288.
Fortin M, D'Anjou H, Higgins ME, Gougeon J, Aubé P, Moktefi K, Mouissi S, Séguin S, Séguin R, Renzi PM, Paquet L and Ferrari N (2009) A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. *Respir Res* **10**:39.

Fouda A, Abdelaziz AE, Hussien M, Ali AA, Abdelkawy KS and Elbarbry F (2021) A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients. *Eur Rev Med Pharmacol Sci* **25**:7449-7459.

Fox 3rd D, Burgin AB and Gurney ME (2014) Structural basis for the design of selective phosphodiesterase 4B inhibitors. *Cellular signalling* **26**:657-663.

Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L and Scurti M (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mechanisms of ageing and development* **128**:92-105.

Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ and Page CP (2013) Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. *Lancet Respir Med* **1**:714-727.

Francis SH, Blount MA and Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. *Physiol Rev* **91**:651-690.

Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA and Corbin JD (2006) Phosphodiesterase 5: molecular characteristics relating to structure, function, and regulation, in *Cyclic Nucleotide Phosphodiesterases in Health and Disease* (Beavo JA, Francis SH and Houslay MD eds) pp 131-164, CRC Press, Boca Raton, FL.

Frid MG, Thurman JM, Hansen KC, Maron BA and Stenmark KR (2020) Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement? *Glob Cardiol Sci Pract* **2020**:e202001.

Frolich L, Wunderlich G, Thamer C, Roehrle M, Garcia M, Jr. and Dubois B (2019) Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. *Alzheimer's research & therapy* **11**:18.

Fujimura M, Kamio Y, Myou S, Hashimoto T and Matsuda T (1997) Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma. *Int Arch Allergy Immunol* **114**:379-384.

Fujimura M, Kamio Y, Saito M, Hashimoto T and Matsuda T (1995) Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. *Am J Respir Crit Care Med* **151**:222-225.

Fujimura M, Tachibana H, Myou S, Kita T and Matsuda T (1998) Bronchoprotective effect of an intrabronchial administration of cilostazol powder and a nebulized PDE1 and PDE4 inhibitor KF19514 in guinea pigs. *Int Arch Allergy Immunol* **116**:220-227.

Fujishige K, Kotera J, Yuasa K and Omori K (2000) The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. *Eur J Biochem* **267**:5943-5951.

Fukuma N, Takimoto E, Ueda K, Liu P, Tajima M, Otsu Y, Kariya T, Harada M, Toko H, Koga K, Blanton RM, Jr., Karas RH and Komuro I (2020) Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy. *JACC Basic Transl Sci* **5**:282-295.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R and Alvarez N (2018) Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. *Cancer medicine* **7**:3474-3483.

Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial H and Response to Tadalafil Study G (2009) Tadalafil therapy for pulmonary arterial hypertension. *Circulation* **119**:2894-2903.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G and Sildenafil Use in Pulmonary Arterial Hypertension Study G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med* **353**:2148-2157.

Galon J and Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat Rev Drug Discov* **18**:197-218.

Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J and Omori K (2003) Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. *Cell Signal* **15**:565-574.

Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A and Hatzelmann A (1998) Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. *Br J Pharmacol* **123**:1031-1038.

Gantner F, Kupferschmidt R, Schudt C, Wendel A and Hatzelmann A (1997a) In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. *Br J Pharmacol* **121**:221-231.

Gantner F, Kusters S, Wendel A, Hatzelmann A, Schudt C and Tiegs G (1997b) Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. *J Pharmacol Exp Ther* **280**:53-60.

Gantner F, Schudt C, Wendel A and Hatzelmann A (1999) Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. *Pulm Pharmacol Ther* **12**:377-386.

Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A and Hatzelmann A (1997c) Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. *J Allergy Clin Immunol* **100**:527-535.

Gao R, Guo W, Fan T, Pang J, Hou Y, Feng X, Li B, Ge W, Fan T, Zhang T, Lu J, Jing H, Jin M, Yan C and Wang J (2022) Phosphodiesterase 4D contributes to angiotensin II-induced abdominal aortic aneurysm through smooth muscle cell apoptosis. *Exp Mol Med* **54**:1201-1213.

Garcia-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Salles J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M and Garcia-Osta A (2013) Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. *Neuropharmacology* **64**:114-123.

Garcia AM, Brea J, Morales-Garcia JA, Perez DI, Gonzalez A, Alonso-Gil S, Gracia-Rubio I, Ros-Simo C, Conde S and Cadavid MI (2014a) Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. *Journal of Medicinal Chemistry* **57**:8590-8607.

Garcia AM, Brea J, Morales-Garcia JA, Perez DI, Gonzalez A, Alonso-Gil S, Gracia-Rubio I, Ros-Simo C, Conde S, Cadavid MI, Loza MI, Perez-Castillo A, Valverde O, Martinez A and Gil C (2014b) Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. *Journal of medicinal chemistry* **57**:8590-8607.

Garcia AR, Blanco I, Ramon L, Perez-Sagredo J, Guerra-Ramos FJ, Martin-Ontiyuelo C, Tura-Ceide O, Pastor-Perez F, Escribano-Subias P and Barbera JA (2023) Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry. *Respir Res* **24**:223.

Garrido AM, Kaistha A, Uryga AK, Oc S, Foote K, Shah A, Finigan A, Figg N, Dobnikar L, Jorgensen H and Bennett M (2022) Efficacy and limitations of senolysis in atherosclerosis. *Cardiovasc Res* **118**:1713-1727.

Garrison G, Huang SK, Okunishi K, Scott JP, Kumar Penke LR, Scruggs AM and Peters-Golden M (2013) Reversal of myofibroblast differentiation by prostaglandin E(2). *Am J Respir Cell Mol Biol* **48**:550-558.

Gauvreau GM, El-Gammal Al and O'Byrne PM (2015) Allergen-induced airway responses. *Eur Respir J* **46**:819-831.

Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA and Rudensky AY (2007) Foxp3-dependent programme of regulatory T-cell differentiation. *Nature* **445**:771-775.
Geerts H, Spiros A and Roberts P (2017) Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. *Expert review of neurotherapeutics* **17**:553-560.

Geoffroy V, Fouque F, Lugnier C, Desbuquois B and Benelli C (2001) Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction. *Arch Biochem Biophys* **387**:154-162.

Ghofrani HA, D'Armini AM, Kim NH, Mayer E and Simonneau G (2021) Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. *Respir Med* **177**:106293.

Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M and Grimminger F (2004a) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. *J Am Coll Cardiol* **43**:68S-72S.

Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W and Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol* **42**:158-164.

Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W and Grimminger F (2002) Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. *Crit Care Med* **30**:2489-2492.

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W and Grimminger F (2004b) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *J Am Coll Cardiol* **44**:1488-1496.

Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS and Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. *PloS one* **5**:e13417.

Giampa C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS and Fusco FR (2009) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. *Neurobiology of disease* **34**:450-456.

Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med* **328**:1313-1316.

Giembycz MA (1992) Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? *Biochem Pharmacol* **43**:2041-2051.

Giembycz MA (1996) Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. *Trends Pharmacol Sci* **17**:331-336.

Giembycz MA (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. *Expert Opin Investig Drugs* **10**:1361-1379.

Giembycz MA (2002) 4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? *Trends Pharmacol Sci* **23**:548.

Giembycz MA (2005a) Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. *Curr Opin Pharmacol* **5**:238-244.

Giembycz MA (2005b) Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society* **2**:326-333.

Giembycz MA (2006) An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. *Br J Clin Pharmacol* **62**:138-152.

Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? *Br J Pharmacol* **155**:288-290.

Giembycz MA (2009) An estimation of β₂-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. *Br J Pharmacol* **158**:287-299.
Giembycz MA and Barnes PJ (1991) Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Relevance to the spasmolytic and anti-spasmogenic actions of AH 21-132 in the intact tissue. *Biochem Pharmacol* **42**:663-677.

Giembycz MA, Corrigan CJ, Seybold J, Newton R and Barnes PJ (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. *Br J Pharmacol* **118**:1945-1958.

Giembycz MA and Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. *Drug Des Devel Ther* **4**:147-158.

Giembycz MA, Kaur M, Leigh R and Newton R (2008) A Holy Grail of asthma management: toward understanding how long-acting β₂-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. *British Journal of Pharmacology* **153**:1090-1104.

Giembycz MA and Maurice DH (2014) Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. *Curr Opin Pharmacol* **16**:89-107.

Giembycz MA and Newton R (2011) Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. *Handbook of Experimental Pharmacology* **204**:415-446.

Giembycz MA and Newton R (2014) How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. *Clin Chest Med* **35**:203-217.

Giembycz MA and Newton R (2015) Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. *F1000Prime Rep* **7**:16.

Giembycz MA and Smith SJ (2006a) Phosphodiesterase 7 as a therapeutic target. *Drug Future* **31**:207.

Giembycz MA and Smith SJ (2006b) Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? *Curr Pharm Des* **12**:3207-3220.

Gilbert EF, Bruyere HJ, Jr., Ishikawa S, Cheung MO and Hodach RJ (1977) The effects of methylxanthines on catecholamine-stimulated and normal chick embryos. *Teratology* **16**:47-52.

Gilotra NA, DeVore AD, Povsic TJ, Hays AG, Hahn VS, Agunbiade TA, DeLong A, Satlin A, Chen R, Davis R and Kass DA (2021) Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. *Circ Heart Fail* **14**:e008236.

Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F and MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. *Human molecular genetics* **12**:497-508.

Giorgi M, D'Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G and Sancesario G (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. *European Journal of Neuroscience* **28**:941-950.

Giralt A, Saavedra A, Carreton O, Arumi H, Tyebji S, Alberch J and Perez-Navarro E (2013) PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. *Hippocampus* **23**:684-695.

Glavas NA, Ostenson C, Schaefer JB, Vasta V and Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. *Proc Natl Acad Sci U S A* **98**:6319-6324.

Gobejishvili L, Avila DV, Barker DF, Ghare S, Henderson D, Brock GN, Kirpich IA, Joshi-Barve S, Mokshagundam SP, McClain CJ and Barve S (2011) S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. *J Pharmacol Exp Ther* **337**:433-443.

Gobejishvili L, Barve S, Breitkopf-Heinlein K, Li Y, Zhang J, Avila DV, Dooley S and McClain CJ (2013) Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4. *J Pharmacol Exp Ther* **347**:80-90.
Gobejishvili L, Barve S, Joshi-Barve S and McClain C (2008) Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. *Am J Physiol Gastrointest Liver Physiol* **295**:G718-724.

Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z and McClain C (2006) Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. *Am J Physiol Gastrointest Liver Physiol* **291**:G681-688.

Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA and Walsh JP (2009) A placebo-controlled study of sildenafil effects on cognition in schizophrenia. *Psychopharmacology* **202**:411-417.

Goldman-Rakic PS, Muly Iii EC and Williams GV (2000) D1 receptors in prefrontal cells and circuits. *Brain Research Reviews* **31**:295-301.

Golshiri K, Ataabadi EA, Juttner AA, Snyder GL, Davis RE, Lin A, Zhang L, de Vries R, Garrelds IM, Leijten FPJ, Danser AHJ and Roks AJM (2021a) The Effects of Acute and Chronic Selective Phosphodiesterase 1 Inhibition on Smooth Muscle Cell-Associated Aging Features. *Front Pharmacol* **12**:818355.

Golshiri K, Ataei Ataabadi E, Brandt R, van der Pluijm I, de Vries R, Danser J and Roks A (2020) Chronic Sildenafil Treatment Improves Vasomotor Function in a Mouse Model of Accelerated Aging. *Int J Mol Sci* **21**.

Golshiri K, Ataei Ataabadi E, Portilla Fernandez EC, Jan Danser AH and Roks AJM (2019) The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase. *Basic Clin Pharmacol Toxicol* **127**:14.

Golshiri K, Ataei Ataabadi E, Rubio-Beltran E, Dutheil S, Yao W, Snyder GL, Davis RE, van der Pluijm I, Brandt R, van den Berg-Garrelds IM, MaassenVanDenBrink A, de Vries R, Danser AHJ and Roks AJM (2021b) Selective PDE1 inhibition ameliorates vascular function, reduces inflammatory response, and lowers blood pressure in ageing animals. *J Pharmacol Exp Ther* **378**:173-183.

Gomaa AA, Farghaly HSM, Ahmed AM and Hemida FK (2023) Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats. *International immunopharmacology* **117**:109927.

Gomez L and Breitenbucher JG (2013) PDE2 inhibition: potential for the treatment of cognitive disorders. *Bioorganic & medicinal chemistry letters* **23**:6522-6527.

Goncalves RL, Lugnier C, Keravis T, Lopes MJ, Fantini FA, Schmitt M, Cortes SF and Lemos VS (2009) The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. *Eur J Pharmacol* **620**:78-83.

Gorelick AN, Sanchez-Rivera FJ, Cai Y, Bielski CM, Biederstedt E, Jonsson P, Richards AL, Vasan N, Penson AV, Friedman ND, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe SW, Reznik E and Taylor BS (2020) Phase and context shape the function of composite oncogenic mutations. *Nature* **582**:100-103.

Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Inoue H, Murafuji H, Hayashi Y, Miura K, Nakatsuka T, Nagahira K, Chamoto K, Fukuda Y and Nishimura T (2009) Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells. *Cell Immunol* **258**:147-151.

Grammatika Pavlidou N, Dobrev S, Beneke K, Reinhardt F, Pecha S, Jacquet E, Abu-Taha IH, Schmidt C, Voigt N, Kamler M, Schnabel RB, Baczko I, Garnier A, Reichenspurner H, Nikolaev VO, Dobrev D and Molina CE (2023) Phosphodiesterase 8 governs cAMP/PKA-dependent reduction of L-type calcium current in human atrial fibrillation: a novel arrhythmogenic mechanism. *Eur Heart J*:2483-2494.

Grange M, Sette C, Cuomo M, Conti M, Lagarde M, Prigent AF and Nemoz G (2000) The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. *Consequences for cAMP*
signaling pathway and characterization of a phosphatidic acid binding site. *J Biol Chem* **275**:33379-33387.

Grass H, Klotz T, Fathian-Sabet B, Berghaus G, Engelmann U and Kaferstein H (2001) Sildenafil (Viagra): is there an influence on psychological performance? *International urology and nephrology* **32**:409-412.

Gredic M, Blanco I, Kovacs G, Helyes Z, Ferdinandy P, Olschewski H, Barbera JA and Weissmann N (2021) Pulmonary hypertension in chronic obstructive pulmonary disease. *Br J Pharmacol* **178**:132-151.

Greengard P, Allen PB and Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. *Neuron* **23**:435-447.

Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA and Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. *Nature* **446**:153-158.

Greer S, Page CW, Joshi T, Yan D, Newton R and Giembycz MA (2013) Concurrent agonism of adenosine A₂b and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease. *J Pharmacol Exp Ther* **346**:473-485.

Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K and Gulcher JR (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. *Nat Genet* **35**:131-138.

Grondin R, Doan VD, Grégoire L and Bédard PJ (1999) D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. *Neurology* **52**:771-771.

Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A and Schultz JE (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. *The Journal of biological chemistry* **281**:2841-2846.

Gross NJ, Giembycz MA and Rennard SI (2010) Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. *Copa* **7**:141-153.

Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH and Wharton J (2006) Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. *Respir Res* **7**:9.

Guellich A, Mehel H and Fischmeister R (2014) Cyclic AMP synthesis and hydrolysis in the normal and failing heart. *Pflugers Arch* **466**:1163-1175.

Gulati S, Palczewski K, Engel A, Stahlberg H and Kovacik L (2019) Cryo-EM structure of phosphodiesterase 6 reveals insights into the allosteric regulation of type I phosphodiesterases. *Sci Adv* **5**:eaav4322.

Gulliver C, Huss S, Semjonow A, Baillie GS and Hoffmann R (2022) The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes. *Cancers (Basel)* **15**.

Gulliver C, Huss S, Semjonow A, Baillie GS and Hoffmann R (2023a) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies. *Br J Cancer*.

Gulliver C, Huss S, Semjonow A, Baillie GS and Hoffmann R (2023b) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies. *Br J Cancer* **129**:1462-1476.
Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J and Pitts WJ (2009) Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. *Bioorg Med Chem Lett* **19**:1935-1938.

Gurney ME, Burgin AB, Magnusson OT and Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. *Handbook of Experimental Pharmacology* **204**:167-192.

Gurney ME, Cogram P, Deacon RM, Rex C and Tranfaglia M (2017) Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). *Scientific reports* **7**:14653.

Gurney ME, Nugent RA, Mo X, Sindac JA, Hagen TJ, Fox D, 3rd, O'Donnell JM, Zhang C, Xu Y, Zhang HT, Groppi VE, Bailie M, White RE, Romero DL, Vellekoop AS, Walker JR, Surman MD, Zhu L and Campbell RF (2019) Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. *J Med Chem* **62**:4884-4901.

Gurpinar E, Grizzle WE and Piazza GA (2014) NSAIDs inhibit tumorigenesis, but how? *Clin Cancer Res* **20**:1104-1113.

Gutierrez-Canas I, Rodriguez-Henche N, Bolanos O, Carmena MJ, Prieto JC and Juarranz MG (2003) VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. *Br J Pharmacol* **139**:1050-1058.

Hait WN and Weiss B (1976) Increased cyclic nucleotide phosphodiesterase activity in leukaemic lymphocytes. *Nature* **259**:321-323.

Hamilton A, Faiferman I, Stober P, Watson RM and O'Byrne PM (1998) Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. *J Allergy Clin Immunol* **102**:177-183.

Hanahan D and Weinberg RA (2000) The hallmarks of cancer. *cell* **100**:57-70.

Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. *cell* **144**:646-674.

Hansen JN, Kaiser F, Leyendecker P, Stuven B, Krause JH, Derakhshandeh F, Irfan J, Sroka TJ, Preval KM, Desai PB, Kraut M, Theis H, Drews AD, De-Domenico E, Handler K, Pazour GJ, Henderson DJP, Mick DU and Wachten D (2022) A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation. *EMBO Rep* **23**:e54315.

Hansen RT, 3rd, Conti M and Zhang HT (2014) Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior. *Psychopharmacology* **231**:2941-2954.

Hanson A (2003) Why rats can't vomit. *Rat Behavior and Biology*.

Harada A, Suzuki K and Kimura H (2017) TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease. *The Journal of pharmacology and experimental therapeutics* **360**:75-83.

Harada N, Nishiyama S, Ohba H, Sato K, Kakiuchi T and Tsukada H (2002) Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys. *Synapse* **44**:139-145.

Hartley BS (1964) The structure and activity of chymotrypsin, in *Struct Activ Enzymes Fed Eur Biochem Soc Symp 1st*.

Hartupee J and Mann DL (2017) Neurohormonal activation in heart failure with reduced ejection fraction. *Nat Rev Cardiol* **14**:30-38.

Hasan N, Zameer S, Najmi AK, Parvez S and Akhtar M (2022) Roflumilast Reduces Pathological Symptoms of Sporadic Alzheimer's Disease in Rats Produced by Intracerebroventricular Streptozotocin by Inhibiting NF-kappaB/BACE-1 Mediated Abeta Production in the Hippocampus and Activating the cAMP/BDNF Signalling Pathway. *Neurotoxicity research* **40**:432-448.

Hashimoto A, Miyakoda G, Hirose Y and Mori T (2006) Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. *Atherosclerosis* **189**:350-357.
Hashimoto T, Kim GE, Tunin RS, Adesiyun T, Hsu S, Nakagawa R, Zhu G, O'Brien JJ, Hendrick JP, Davis RE, Yao W, Beard D, Hoxie HR, Wennogle LP, Lee DI and Kass DA (2018) Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition. *Circulation* **138**:1974-1987.

Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, Halama N, Dimitrakopoulou-Strauss A, Haefeli WE, Jäger D, Enk A, Utikal J and Umansky V (2017) Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). *Oncoimmunology* **6**:e1326440.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C and Tenor H (2010) The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. *Pulm Pharmacol Ther* **23**:235-256.

Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. *J Pharmacol Exp Ther* **297**:267-279.

Havekes R, Park AJ, Tolentino RE, Bruinenberg VM, Tudor JC, Lee Y, Hansen RT, Guercio LA, Linton E, Neves-Zaph SR, Meerlo P, Baillie GS, Houslay MD and Abel T (2016a) Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **36**:8936-8946.

Havekes R, Park AJ, Tudor JC, Luczak VG, Hansen RT, Ferri SL, Bruinenberg VM, Poplawski SG, Day JP, Aton SJ, Radwanska K, Meerlo P, Houslay MD, Baillie GS and Abel T (2016b) Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1. *eLife* **5**.

Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y and Tanaka T (1998) Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. *Biochem Biophys Res Commun* **250**:751-756.

Hayes JS, Brunton LL and Mayer SE (1980) Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. *J Biol Chem* **255**:5113-5119.

Haynes J, Jr., Killilea DW, Peterson PD and Thompson WJ (1996) Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. *J Pharmacol Exp Ther* **276**:752-757.

Healy LM and Antel JP (2016) Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems. *Curr Drug Targets* **17**:1841-1850.

Hebb AL, Robertson HA and Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. *Neuroscience* **123**:967-981.

Heckman PRA, Blokland A, Bollen EPP and Prickaerts J (2018a) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. *Neuroscience and biobehavioral reviews* **87**:233-254.

Heckman PRA, Van Duinen MA, Blokland A, Uz T, Prickaerts J and Sambeth A (2018b) Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial. *Psychopharmacology* **235**:301-308.

Hedde JR, Hanks AN, Schmidt CJ and Hughes ZA (2017) The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation. *Brain, behavior, and immunity* **64**:285-295.

Hegde S, Capell WR, Ibrahim BA, Klett J, Patel NS, Sougiannis AT and Kelly MP (2016) Phosphodiesterase 11A (PDE11A), Enriched in Ventral Hippocampus Neurons, is Required for Consolidation of Social but not Nonsocial Memories in Mice. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* **41**:2920-2931.

Heikaus CC, Pandit J and Klevit RE (2009) Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. *Structure* **17**:1551-1557.

Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA and Klevit RE (2008) Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. *J Biol Chem* **283**:22749-22759.
Henderson DJ, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS and Houslay MD (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. *Br J Cancer* **110**:1278-1287.

Henderson DJP, Houslay MD, Bangma CH and Hoffmann R (2019) Creating a potential diagnostic for prostate cancer risk stratification (InformMDx) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). *Clin Sci (Lond)* **133**:269-286.

Henning NJ, Boike L, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse MJ, Dovala D, McGregor LM, Valdez Misiolek R, Plasschaert LW, Rowlands DJ, Wang F, Frank AO, Fuller D, Estes AR, Randal KL, Panidapu A, McKenna JM, Tallarico JA, Schirle M and Nomura DK (2022) Deubiquitinase-targeting chimeras for targeted protein stabilization. *Nat Chem Biol* **18**:412-421.

Herget S, Lohse MJ and Nikolaev VO (2008) Real-time monitoring of phosphodiesterase inhibition in intact cells. *Cell Signal* **20**:1423-1431.

Herrmann FE, Hesslinger C, Wollin L and Nickolaus P (2022) BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. *Front Pharmacol* **13**:838449.

Herrmann HC, Chang G, Klugherz BD and Mahoney PD (2000) Hemodynamic effects of sildenafil in men with severe coronary artery disease. *N Engl J Med* **342**:1622-1626.

Hertz AL and Beavo JA (2011) Cyclic nucleotides and phosphodiesterases in monocytic differentiation. *Handb Exp Pharmacol*:365-390.

Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS and Kool M (2019) Inflammation and immunity in IPF pathogenesis and treatment. *Respir Med* **147**:79-91.

Heystek HC, Thierry AC, Soulard P and Moulon C (2003) Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. *Int Immunol* **15**:827-835.

Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T and Saitoh Y (1979) Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. *J Pharmacol Exp Ther* **211**:26-30.

Hindmarch I, Fuchs HH and Erzigkeit H (1991) Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. *International clinical psychopharmacology* **6**:31-43.

Hiramoto K, Murata T, Shimizu K, Morita H, Inui M, Manganiello VC, Tagawa T and Arai N (2014) Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells. *Cell Signal* **26**:1807-1817.

Hogg JC (1996) Airway behavior and its regulation: how do structural changes affect airway behavior? *Am J Respir Crit Care Med* **153**:S16-18.

Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. *Lancet* **364**:709-721.

Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO and Paré PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* **350**:2645-2653.

Hogg JC and Timens W (2009) The pathology of chronic obstructive pulmonary disease. *Annu Rev Pathol* **4**:435-459.

Hopkins SR and Stickland MK (2023) The Pulmonary Vasculature. *Semin Respir Crit Care Med* **44**:538-554.

Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ and Andrews PL (2013) Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study. *PLoS One* **8**:e60537.

Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. *Pharmacological reviews* **18**:925-964.

Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, de Herder W, Carney JA, Bertherat J, Gregersen PK, Remmers EF and Stratakis CA (2006) Adrenal
hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. *Cancer research* **66**:11571-11575.

Horvath A, Korde L, Greene MH, Libe R, Osorio P, Faucz FR, Raffin-Sanson ML, Tsang KM, Drori-Herishanu L, Patronas Y, Remmers EF, Nikita ME, Moran J, Greene J, Nesterova M, Merino M, Bertherat J and Stratakis CA (2009) Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. *Cancer research* **69**:5301-5306.

Hossain S and Heard BE (1970) Hyperplasia of bronchial muscle in chronic bronchitis. *J Pathol* **101**:171-184.

Houglum K, Lee KS and Chojkier M (1997) Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. *J Clin Invest* **99**:1322-1328.

Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* **69**:249-315.

Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. **35**:91-100.

Houslay MD and Adams DR (2010) Putting the lid on phosphodiesterase 4. *Nat Biotechnol* **28**:38-40.

Houslay MD and Baillie GS (2005) Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK. *Biochemical Society transactions* **33**:1333-1336.

Houslay MD, Baillie GS and Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. *Circ Res* **100**:950-966.

Houslay MD, Schafer P and Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. *Drug Discov Today* **10**:1503-1519.

Hsu CG, Fazal F, Rahman A, Berk BC and Yan C (2021) Phosphodiesterase 10A Is a Key Mediator of Lung Inflammation. *J Immunol* **206**:3010-3020.

Hu A, Nino G, Grunstein JS, Fatma S and Grunstein MM (2008) Prolonged heterologous β₂-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction. *American Journal of Physiology Lung Cellular and Molecular Physiology* **294**:L1055-1067.

Hu H, McCaw EA, Hebb AL, Gomez GT and Denovan-Wright EM (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. *The European journal of neuroscience* **20**:3351-3363.

Hu SW, Wang YH, Huang JS, Yang YM, Wu CC and Cheng CW (2022) The PDE5 inhibitor, vardenafil, ameliorates progressive pathological changes in a focal segmental glomerulosclerosis mouse model. *Life Sci* **309**:120992.

Huai Q, Colicelli J and Ke H (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. *Biochemistry* **42**:13220-13226.

Huang JX, Zhu BL, Xu JP and Zhou ZZ (2023) Advances in the development of phosphodiesterase 7 inhibitors. *Eur J Med Chem* **250**:115194.

Huang L, Shan W, Zhou Q, Xie J, Lai K and Li X (2014) Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. *Bioorg Med Chem Lett* **24**:249-253.

Huang M, Shao Y, Hou J, Cui W, Liang B, Huang Y, Li Z, Wu Y, Zhu X, Liu P, Wan Y, Ke H and Luo HB (2015) Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor. *Mol Pharmacol* **88**:836-845.

Huang MX, Tian YJ, Han C, Liu RD, Xie X, Yuan Y, Yang YY, Li Z, Chen J, Luo HB and Wu Y (2022) Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. *J Med Chem* **65**:8444-8455.

Huang W, Sundquist J, Sundquist K and Ji J (2019a) Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms. *Gastroenterology* **157**:672-681.e674.

Huang W, Sundquist J, Sundquist K and Ji J (2020a) Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. *Nat Commun* **11**:3191.
Huang XF, Dong YH, Wang JH, Ke HM, Song GQ and Xu DF (2020b) Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease. *Bioorganic & medicinal chemistry letters* **30**:127097.

Huang Y, Wu XN, Zhou Q, Wu Y, Zheng D, Li Z, Guo L and Luo HB (2020c) Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors. *Journal of medicinal chemistry* **63**:15852-15863.

Huang YY, Yu YF, Zhang C, Chen Y, Zhou Q, Li Z, Zhou S, Li Z, Guo L, Wu D, Wu Y and Luo HB (2019b) Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. *J Med Chem* **62**:3707-3721.

Huertas A, Guignabert C, Barbera JA, Bartsch P, Bhattacharya J, Bhattacharya S, Bonsignore MR, Dewachter L, Dinh-Xuan AT, Dorfmuller P, Gladwin MT, Humbert M, Kotsimbos T, Vassilakopoulos T, Sanchez O, Savale L, Testa U and Wilkins MR (2018) Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. *Eur Respir J* **51**.

Huggins C and Hodges CV (1941) Studies on prostate cancer I: effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res* **1**:293-297.

Hughes AD, Chin KH, Dunham SL, Jasper JR, King KE, Lee TW, Mammen M, Martin J and Steinfeld T (2011) Discovery of muscarinic acetylcholine receptor antagonist and β₂-adrenoceptor agonist (MABA) dual pharmacology molecules. *Bioorganic & medicinal chemistry letters* **21**:1354-1358.

Humbert M and Ghofrani HA (2016) The molecular targets of approved treatments for pulmonary arterial hypertension. *Thorax* **71**:73-83.

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachieri JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S and Group EESD (2022) 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* **43**:3618-3731.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF and Wedzicha JA (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* **363**:1128-1138.

Huston E, Gall I, Houslay TM and Houslay MD (2006) Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+. *Journal of cell science* **119**:3799-3810.

Iancu RV, Jones SW and Harvey RD (2007) Compartmentation of cAMP signaling in cardiac myocytes: a computational study. *Biophys J* **92**:3317-3331.

Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, Takahashi Y, Tsuji M, Kasahara Y, Takata Y and Okada M (2014) Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. *PloS one* **9**:e89516.

Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G and Chiariello M (1997) Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. *Nat Med* **3**:775-779.

Inoue Y, Toga K, Sudo T, Tachibana K, Tochizawa S, Kimura Y, Yoshida Y and Hidaka H (2000) Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. *Br J Pharmacol* **130**:231-241.

Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D and Aroonsakool N (2012) cAMP and Epac in the regulation of tissue fibrosis. *Br J Pharmacol* **166**:447-456.

Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, Rasmussen SG, Sunahara RK, El-Samad H, Huang B and von Zastrow M (2013) Conformational biosensors reveal GPCR signalling from endosomes. *Nature* **495**:534-538.
Irwin MJ, Gupta R, Gao XZ, Cahill KB, Chu F and Cote RH (2019) The molecular architecture of photoreceptor phosphodiesterase 6 (PDE6) with activated G protein elucidates the mechanism of visual excitation. *J Biol Chem* **294**:19486-19497.

Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, Togo M, Miki K, Kurokawa K and Ohno M (1999) Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. *Atherosclerosis* **142**:41-46.

Islam BN, Sharman SK, Hou Y, Bridges AE, Singh N, Kim S, Kolhe R, Trillo-Tinoco J, Rodriguez PC and Berger FG (2017) Sildenafil suppresses inflammation-driven colorectal cancer in mice. *Cancer Prevention Research* **10**:377-388.

Ito M, Okamoto R, Ito H, Zhe Y and Dohi K (2022) Regulation of myosin light-chain phosphorylation and its roles in cardiovascular physiology and pathophysiology. *Hypertens Res* **45**:40-52.

Ito T, Zhang E, Omori A, Kabwe J, Kawai M, Maruyama J, Okada A, Yokochi A, Sawada H, Mitani Y and Maruyama K (2021) Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats. *BMC Pulm Med* **21**:377.

Iwasaki T, Onda T, Honda H, Hayashi K, Shibahara T, Nomura T and Takano M (2021) Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate. *Anticancer Res* **41**:2297-2306.

Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S and Eddahibi S (2009) Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. *J Pharmacol Exp Ther* **330**:54-62.

Jager R, Russwurm C, Schwede F, Genieser HG, Koesling D and Russwurm M (2012) Activation of PDE10 and PDE11 phosphodiesterases. *J Biol Chem* **287**:1210-1219.

Jalencas X and Mestres J (2013) On the origins of polypharmacology. *Med Chem Commun* **4**:80.

James AT, Corcoran JD, McNamara PJ, Franklin O and El-Khuffash AF (2016) The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension. *Cardiol Young* **26**:90-99.

Jankovic J and Aguilar LG (2008) Current approaches to the treatment of Parkinson's disease. *Neuropsychiatric disease and treatment* **4**:743-757.

Jankowska A, Swierczek A, Chlon-Rzepa G, Pawlowski M and Wyska E (2017a) PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. *Current medicinal chemistry* **24**:673-700.

Jankowska A, Swierczek A, Chlon-Rzepa G, Pawlowski M and Wyska E (2017b) PDE7 - Selective and dual inhibitors: advances in chemical and biological research. *Current medicinal chemistry* **24**:673-700.

Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E and Lebwohl MG (2016) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. *J Drugs Dermatol* **15**:390-396.

Jeffery PK (2001) Remodeling in asthma and chronic obstructive lung disease. *Am J Respir Crit Care Med* **164**:S28-38.

Jeffery TK and Wanstall JC (1998) Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. *J Cardiovasc Pharmacol* **32**:213-219.

Jellinger KA (1991) Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. *Molecular and chemical neuropathology* **14**:153-197.

Jiang X, Li J, Paskind M and Epstein PM (1996) Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. *Proc Natl Acad Sci U S A* **93**:11236-11241.

Jiang X, Paskind M, Weltzien R and Epstein PM (1998) Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. *Cell Biochem Biophys* **28**:135-160.

Jimenez JL, Iniguez MA, Munoz-Fernandez MA and Fresno M (2004) Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. *Cell Signal* **16**:1363-1373.
Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA and Fresno M (2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. *J Pharmacol Exp Ther* **299**:753-759.

Jin SL, Bushnik T, Lan L and Conti M (1998) Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. *J Biol Chem* **273**:19672-19678.

Jin SL and Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. *Proc Natl Acad Sci U S A* **99**:7628-7633.

Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, Umetsu D and Conti M (2010) Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. *J Allergy Clin Immunol* **126**:1252-1259 e1212.

Jin SL, Lan L, Zoudilova M and Conti M (2005) Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages. *J Immunol* **175**:1523-1531.

Johnstone TB, Smith KH, Koziol-White CJ, Li F, Kazarian AG, Corpuz ML, Shumatcher M, Ehlert FJ, Himes BE, Panettieri RA, Jr. and Ostrom RS (2017) PDE8 is Expressed in Human Airway Smooth Muscle and Selectively Regulates cAMP Signaling by beta2AR-AC6. *Am J Respir Cell Mol Biol.*

Johnstone TB, Smith KH, Koziol-White CJ, Li F, Kazarian AG, Corpuz ML, Shumatcher M, Ehlert FJ, Himes BE, Panettieri RA, Jr. and Ostrom RS (2018) PDE8 Is Expressed in Human Airway Smooth Muscle and Selectively Regulates cAMP Signaling by β(2)-Adrenergic Receptors and Adenylyl Cyclase 6. *Am J Respir Cell Mol Biol* **58**:530-541.

Jones NA, Boswell-Smith V, Lever R and Page CP (2005) The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. *Pulm Pharmacol Ther* **18**:93-101.

Jones NA, Leport M, Holand T, Vos T, Morgan M, Fink M, Pruniaux MP, Berthelier C, O'Connor BJ, Bertrand C and Page CP (2007) Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. *Pulm Pharmacol Ther* **20**:60-68.

Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA and Shah VH (2024) ACG Clinical Guideline: Alcohol-Associated Liver Disease. *Am J Gastroenterol* **119**:30-54.

Joshi T, Johnson M, Newton R and Giembycz MA (2015) The long-acting β₂-adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner. *Br J Pharmacol* **172**:2634-2653.

Joshi T, Yan D, Hamed O, Tannheimer SL, Phillips GB, Wright CD, Kim M, Salmon M, Newton R and Giembycz MA (2017) GS-5759, a bifunctional β₂-adrenoceptor agonist and phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease with a unique mode of action: effects on gene expression in human airway epithelial cells. *J Pharmacol Exp Ther* **360**:324-340.

Jouabadi SM, Ataabadi EA, Golshiri K, Bos D, Stricker BHC, Danser AHJ, Mattace-Raso F and Roks AJM (2023) Clinical Impact And Mechanisms Of Non-Atherosclerotic Vascular Aging: The New Kid to be Blocked. *Can J Cardiol.*

Jurevicius J and Fischmeister R (1996) cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. *Proc Natl Acad Sci U S A* **93**:295-299.

Justo AFO, Toscano ECB, Farias-Itao DS and Suemoto CK (2023) The action of phosphodiesterase-5 inhibitors on beta-amyloid pathology and cognition in experimental Alzheimer's disease: A systematic review. *Life sciences* **320**:121570.

Jüttner AAD, A.H.J.; Roks, A.J.M. (2022) Pharmacological developments in antihypertensive treatment through nitric oxide—cGMP modulation, in *Advances in Pharmacology*.

Kadoshima-Yamaoka K, Goto M, Murakawa M, Yoshioka R, Tanaka Y, Inoue H, Murafuji H, Kanki S, Hayashi Y, Nagahira K, Ogata A, Nakatsuka T and Fukuda Y (2009a) ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNFα level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in mice. *European journal of pharmacology* **613**:163-166.

Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y and Nishimura T (2009b) Effect of phosphodiesterase
7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. *Int Immunopharmacol* **9**:97-102.

Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y and Nishimura T (2009c) ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. *Immunol Lett* **122**:193-197.

Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y and Nishimura T (2009d) ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFNγ production by mouse activated T lymphocytes. *Immunology letters* **122**:193-197.

Kai Y, Watanabe M, Morioka M, Hirano T, Yano S, Ohmori Y, Kawano T, Hamada J and Kuratsu J (2011) Cilostazol improves symptomatic intracranial artery stenosis - Evaluation of cerebral blood flow with single photon emission computed tomography. *Surgical neurology international* **2**:8.

Kamel R, Bourcier A, Margaria JP, Varin A, Hivonnait A, Mercier-Nomé F, Mika D, Ghigo A, Charpentier F, Algalarrondo V, Hirsch E, Fischmeister R, Vandecasteele G and Leroy J (2023) Cardiac gene therapy with PDE2A limits remodeling and arrhythmias in mouse models of heart failure induced by catecholamines. *bioRxiv* https://doi.org/10.1101/2023.04.17.537274.

Kameni Tcheudji JF, Lebeau L, Virmaux N, Maftei CG, Cote RH, Lugnier C and Schultz P (2001) Molecular organization of bovine rod cGMP-phosphodiesterase 6. *J Mol Biol* **310**:781-791.

Kametani F and Haga S (2015) Accumulation of carboxy-terminal fragments of APP increases phosphodiesterase 8B. *Neurobiology of aging* **36**:634-637.

Kanda N and Watanabe S (2001) Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. *Biochem Pharmacol* **62**:495-507.

Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS and Barclay T (2017) in *Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia*, Rockville (MD).

Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T and Kelly MP (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. *Neuroscience* **144**:239-246.

Kang BW, Kim F, Cho JY, Kim S, Rhee J and Choung JJ (2022) Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions. *Alzheimer's research & therapy* **14**:92.

Karam S, Margaria JP, Bourcier A, Mika D, Varin A, Bedioune I, Lindner M, Bouadjel K, Dessillons M, Gaudin F, Lefebvre F, Mateo P, Lechene P, Gomez S, Domergue V, Robert P, Coquard C, Algalarrondo V, Samuel JL, Michel JB, Charpentier F, Ghigo A, Hirsch E, Fischmeister R, Leroy J and Vandecasteele G (2020) Cardiac overexpression of PDE4B blunts β-adrenergic response and maladaptive remodeling in heart failure. *Circulation* **142**:161-174.

Karampitsakos T, Juan-Guardela BM, Tzouvelekis A and Herazo-Maya JD (2023) Precision medicine advances in idiopathic pulmonary fibrosis. *EBioMedicine* **95**:104766.

Kato H, Araki T, Chen T, Itoyama Y and Kogure K (1998) Effect of rolipram on age-related changes in cyclic AMP-selective phosphodiesterase in the rat brain: an autoradiographic study. *Methods and findings in experimental and clinical pharmacology* **20**:403-408.

Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A and Yasskiy A (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. *Circulation* **111**:310-314.

Kaumann AJ, Galindo-Tovar A, Escudero E and Vargas ML (2009) Phosphodiesterases do not limit β₁-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats. *Naunyn Schmiedebergs Arch Pharmacol* **380**:421-430.
Kaur M, Chivers JE, Giembycz MA and Newton R (2008) Long-acting β₂-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. *Mol Pharmacol* **73**:203-214.

Kayik G, Tuzun NS and Durdagi S (2017) Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. *J Enzyme Inhib Med Chem* **32**:311-330.

Ke H and Wang H (2006) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide phosphodiesterases, in *Cyclic nucleotide phosphodiesterases in health and disease* (Beavo J, Francis D and Houslay MD eds) pp 607-626, CSC Press.

Ke H and Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. *Curr Top Med Chem* **7**:391-403.

Ke H, Wang H and Ye M (2011) Structural insight into the substrate specificity of phosphodiesterases. *Handb Exp Pharmacol*:121-134.

Kedarisetty CK, Bhardwaj A, Kumar G, Rastogi A, Bihari C, Kumar M and Sarin SK (2021) Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis-A randomized pilot study. *Indian J Gastroenterol* **40**:41-49.

Kedia GT, Uckert S, Polat H, Merseburger AS and Kuczyk MA (2012) Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study. *Urology* **80**:952 e959-914.

Keith CT, Borisy AA and Stockwell BR (2005) Multicomponent therapeutics for networked systems. *Nat Rev Drug Discov* **4**:71-78.

Kelly MP (2014) Putting together the pieces of phosphodiesterase distribution patterns in the brain: A jigsaw puzzle of cyclic nucleotide regulation., in *Cyclic Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Disease* (Brandon NJ and West AR eds) pp 47-58, John Wiley & Sons, Inc, New Jersey.

Kelly MP (2015) Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target? *Current pharmaceutical design* **21**:389-416.

Kelly MP (2018a) Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. *Cell Signal* **42**:281-291.

Kelly MP (2018b) Pde11a, in *Encyclopedia of Signaling Molecules* (Choi S ed) pp 1-23, Springer New York, New York, NY.

Kelly MP, Adamowicz W, Bove S, Hartman AJ, Mariga A, Pathak G, Reinhart V, Romegialli A and Kleiman RJ (2014) Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. *Cellular signalling* **26**:383-397.

Kelly MP, Heckman PRA and Havekes R (2020) Genetic manipulation of cyclic nucleotide signaling during hippocampal neuroplasticity and memory formation. *Progress in neurobiology* **190**:101799.

Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD and Brandon NJ (2010) Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. *Proceedings of the National Academy of Sciences of the United States of America* **107**:8457-8462.

Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S, Smith M, Vostrejs WP, Perez-Vale KZ, Kahn B, Mo F, Donahue TR, Radu CG, Clendenin C, Christensen JG, Vonderheide RH and Stanger BZ (2023) Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. *Cancer Discov* **13**:298-311.

Keravis T, Komas N and Lugnier C (2000) Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes. *J Vasc Res* **37**:235-249.

Keravis T and Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. *Br J Pharmacol* **165**:1288-1305.
Keravis T, Thaseldar-Roumie R and Lugnier C (2005) Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. *Methods Mol Biol* **307**:63-74.

Keravis TM, Wells JN and Hardman JG (1980) Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. *Biochim Biophys Acta* **613**:116-129.

Keswani AN, Peyton KJ, Durante W, Schafer AI and Tulis DA (2009) The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. *J Cardiovasc Pharmacol Ther* **14**:116-124.

Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC and Yan C (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. *Circulation* **104**:2338-2343.

Kim SW, Lim JY, Rhee CK, Kim JH, Park CK, Kim TJ, Cho CS, Min CK and Yoon HK (2016) Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice. *Exp Hematol* **44**:332-341 e334.

Kirkham PA and Barnes PJ (2013) Oxidative stress in COPD. *Chest* **144**:266-273.

Kiso H, Ohba T, Iino K, Sato K, Terata Y, Murakami M, Ono K, Watanabe H and Ito H (2013) Sildenafil prevents the up-regulation of transient receptor potential canonical channels in the development of cardiomyocyte hypertrophy. *Biochem Biophys Res Commun* **436**:514-518.

Kita T, Fujimura M, Myou S, Watanabe K, Waseda Y and Nakao S (2009) Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma. *Allergol Int* **58**:267-275.

Klawans HL and Weiner WJ (1974) Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. *Journal of Neurology, Neurosurgery & Psychiatry* **37**:427-430.

Knight WE, Chen S, Zhang Y, Oikawa M, Wu M, Zhou Q, Miller CL, Cai Y, Mickelsen DM, Moravec C, Small EM, Abe J and Yan C (2016a) PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction. *Proc Natl Acad Sci U S A*.

Knight WE, Chen S, Zhang Y, Oikawa M, Wu M, Zhou Q, Miller CL, Cai Y, Mickelsen DM, Moravec C, Small EM, Abe J and Yan C (2016b) PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction. *Proc Natl Acad Sci U S A* **113**:E7116-E7125.

Knorr A, Hirth-Dietrich C, Alonso-Alija C, Harter M, Hahn M, Keim Y, Wunder F and Stasch JP (2008) Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. *Arzneimittelforschung* **58**:71-80.

Kobayashi T, Gamanuma M, Sasaki T, Yamashita Y, Yuasa K, Kotera J and Omori K (2003) Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. *Gene* **319**:21-31.

Koga H, Recke A, Vidarsson G, Pas HH, Jonkman MF, Hashimoto T, Kasprick A, Ghorbanalipoor S, Tenor H, Zillikens D and Ludwig RJ (2016) PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita. *J Invest Dermatol* **136**:2211-2220.

Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS and Rennard SI (2002) PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. *Am J Respir Cell Mol Biol* **26**:694-701.

Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF and Kass DA (2010) Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation. *Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol* **48**:713-724.

Kokkonen K and Kass DA (2017) Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. *Annu Rev Pharmacol Toxicol* **57**:455-479.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ and Investigators I (2018) Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med* **379**:1722-1731.

Kolb M and Vasakova M (2019) The natural history of progressive fibrosing interstitial lung diseases. *Respir Res* **20**:57.
Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger F, Seeger W, Banat GA, Schermuly RT and Pullamsetti SS (2009) Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. *Mol Biol Cell* **20**:4751-4765.

Komas N, Lugnier C, Le Bec A, Serradeil-Le Gal C, Barthelemy G and Stoclet JC (1989) Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. *J Cardiovasc Pharmacol* **14**:213-220.

Konstantinidou M, Li J, Zhang B, Wang Z, Shaabani S, Ter Brake F, Essa K and Domling A (2019) PROTACs-a game-changing technology. *Expert Opin Drug Discov* **14**:1255-1268.

Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A and Deibert P (2021) Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. *Int J Mol Sci* **22**.

Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A and Deibert P (2020) Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. *Int J Mol Sci* **21**.

Kroegel C and Foerster M (2007) Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. *Expert Opin Investig Drugs* **16**:109-124.

Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H and Dorner-Ciossek C (2014) PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. *Neurobiology of aging* **35**:2072-2078.

Krzyzanowski M, Vandenberg J and Stieb D (2005) Perspectives on air quality policy issues in Europe and North America. *J Toxicol Environ Health A* **68**:1057-1061.

Kumar A and Singh N (2017) Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. *Biomedicine & pharmacotherapy* = *Biomedecine & pharmacotherapie* **88**:698-707.

Kumar N, Goldminz AM, Kim N and Gottlieb AB (2013) Phosphodiesterase 4-targeted treatments for autoimmune diseases. *BMC Med* **11**:96.

Kurai D, Saraya T, Ishii H and Takizawa H (2013) Virus-induced exacerbations in asthma and COPD. *Front Microbiol* **4**:293.

Kurakula K, Smolders V, Tura-Ceide O, Jukema JW, Quax PHA and Goumans MJ (2021) Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence? *Biomedicines* **9**.

Kurelic R, Krieg PF, Sonner JK, Bhaiyan G, Ramos GC, Frantz S, Friese MA and Nikolaev VO (2021) Upregulation of Phosphodiesterase 2A Augments T Cell Activation by Changing cGMP/cAMP Cross-Talk. *Front Pharmacol* **12**:748798.

Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S and Schlaudraff F (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. *PloS one* **5**:e11464.

Kvissel AK, Ramberg H, Eide T, Svinland A, Skalhegg BS and Tasken KA (2007) Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. *Cell Signal* **19**:401-409.

Kyurkchieva E and Baillie GS (2023) Short PDE4 Isoforms as Drug Targets in Disease. *Front Biosci (Landmark Ed)* **28**:133.

Lahm T and Chakinala MM (2013) World Health Organization group 5 pulmonary hypertension. *Clin Chest Med* **34**:753-778.

Lajoie AC, Bonnet S and Provencher S (2017) Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. *Pulm Circ* **7**:312-325.

Lakhal K, Hivert A, Alexandre PL, Fresco M, Robert-Edan V, Rodie-Talbere PA, Ambrosi X, Bourcier R, Rozec B and Cadiet J (2021) Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: The MILRISPASM Controlled Before-After Study. *Neurocrit Care* **35**:669-679.

Lakics V, Karran EH and Boess FG (2010a) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. *Neuropharmacology* **59**:367-374.
Lakics V, Karran EH and Boess FG (2010b) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. *Neuropharmacology* **59**:367-374.

Lakshminarayanan S, Antonetti DA, Gardner TW and Tarbell JM (2000) Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. *Invest Ophthalmol Vis Sci* **41**:4256-4261.

Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Boulet L, Pon DJ, Robichaud A, Robertson GS, Metters KM and Nantel F (2001) Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. *Brain Res* **920**:84-96.

Lan TH, Liu Q, Li C, Wu G and Lambert NA (2012) Sensitive and high resolution localization and tracking of membrane proteins in live cells with BRET. *Traffic* **13**:1450-1456.

Lanfear DE, Hasan R, Gupta RC, Williams C, Czerska B, Tita C, Bazari R and Sabbah HN (2009) Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. *J Transl Med* **7**:67.

Laursen M, Beck L, Kehler J, Christoffersen CT, Bundgaard C, Mogensen S, Mow TJ, Pinilla E, Knudsen JS, Hedegaard ER, Grunnet M and Simonsen U (2017) Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. *Br J Pharmacol* **174**:2563-2575.

Lazaar AL and Panettieri RA, Jr. (2003) Is airway remodeling clinically relevant in asthma? *Am J Med* **115**:652-659.

Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. *J Biol Chem* **277**:35980-35989.

Leaker BR, Nicholson GC, Ali FY, Daudi N, O'Connor BJ and Barnes PJ (2015) Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. *Respir Res* **16**:102.

Lee A, Lebedyeva I, Zhi W, Senthil V, Cheema H, Brands MW, Bush W, Lambert NA, Snipes M and Browning DD (2023) A Non-Systemic Phosphodiesterase-5 Inhibitor Suppresses Colon Proliferation in Mice. *Int J Mol Sci* **24**.

Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E and Kass DA (2015) Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. *Nature* **519**:472-476.

Lee J, Zhang J, Chung YJ, Kim JH, Kook CM, Gonzalez-Navajas JM, Herdman DS, Nurnberg B, Insel PA, Corr M, Mo JH, Tao A, Yasuda K, Rifkin IR, Broide DH, Sciammas R, Webster NJ and Raz E (2020) Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. *Elife* **9**.

Lee K, Lindsey AS, Li N, Gary B, Andrews J, Keeton AB and Piazza GA (2016) β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. *Oncotarget* **7**:5353-5365.

Lee KJ, Chang WL, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E, Musiyenko A, Madeira da Silva L, Annamdevula NS, Leavesley SJ, Ward A, Mattox T, Lindsey AS, Andrews J, Zhu B, Wood C, Neese A, Nguyen A, Berry K, Maxuitenko Y, Moyer MP, Nurmemmedov E, Gorman G, Coward L, Zhou G, Keeton AB, Cooper HS, Clapper ML and Piazza GA (2021) Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin. *Cancer Prev Res (Phila)* **14**:995-1008.

Lee LC, Maurice DH and Baillie GS (2013) Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. *Future Med Chem* **5**:451-464.

Lee R, Wolda S, Moon E, Esselstyn J, Hertel C and Lerner A (2002) PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. *Cell Signal* **14**:277-284.

Leeman M, Lejeune P, Melot C and Naeije R (1987) Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. *Chest* **91**:662-666.
Lefkimmiatis K, Leronni D and Hofer AM (2013) The inner and outer compartments of mitochondria are sites of distinct cAMP/PKA signaling dynamics. *J Cell Biol* **202**:453-462.

Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SLC, Conti M and Marks A (2005) Phosphodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. *Cell* **123**:23-35.

Leopold JA and Maron BA (2016) Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. *Int J Mol Sci* **17**.

Lerner A and Epstein PM (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. *Biochem J* **393**:21-41.

Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechene P, Mazet JL, Conti M, Fischmeister R and Vandecasteele G (2008) Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. *Circ Res* **102**:1091-1100.

Leroy J, Richter W, Mika D, Castro LRV, Abi-Gerges A, Xie M, Scheitrum C, Lefebvre F, Schittl J, Westenbroek R, Catterall WA, Charpentier F, Conti M, Fischmeister R and Vandecasteele G (2011) Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias. *J Clin Invest* **121**:2651-2661.

Leslie SN, Datta D, Christensen KR, van Dyck CH, Arnsten AFT and Nairn AC (2020) Phosphodiesterase PDE4D Is Decreased in Frontal Cortex of Aged Rats and Positively Correlated With Working Memory Performance and Inversely Correlated With PKA Phosphorylation of Tau. *Frontiers in aging neuroscience* **12**:576723.

Leszczynska A, Stoess C, Sung H, Povero D, Eguchi A and Feldstein A (2023) Extracellular Vesicles as Therapeutic and Diagnostic Tools for Chronic Liver Diseases. *Biomedicines* **11**.

Leuti A, Laurenti D, Giampa C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G and Fusco FR (2013) Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. *Neurobiology of disease* **52**:104-116.

Li D, Liu K, Davis H, Robertson C, Neely OC, Tarafdar A, Li N, Lefkimmiatis K, Zaccolo M and Paterson DJ (2022) Abnormal Cyclic Nucleotide Signaling at the Outer Mitochondrial Membrane In Sympathetic Neurons During the Early Stages of Hypertension. *Hypertension* **79**:1374-1384.

Li H, Zuo J and Tang W (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. *Front Pharmacol* **9**:1048.

Li J, Liu CN, Wei N, Li XD, Liu YY, Yang R and Jia YJ (2016a) Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-beta peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease. *Brain research* **1642**:327-335.

Li JT, Liao ZX, Ping J, Xu D and Wang H (2008) Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. *J Gastroenterol* **43**:419-428.

Li K and Crews CM (2022) PROTACs: past, present and future. *Chem Soc Rev* **51**:5214-5236.

Li L, Yee C and Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. *Science* **283**:848-851.

Li N, Chen X, Zhu B, Ramírez-Alcántara V, Canzoneri JC, Lee K, Sigler S, Gary B, Li Y and Zhang W (2015a) Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. *Oncotarget* **6**:27403.

Li N, Lee K, Xi Y, Zhu B, Gary BD, Ramírez-Alcántara V, Gurpinar E, Canzoneri JC, Fajardo A and Sigler S (2015b) Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. *Oncogene* **34**:1499-1509.

Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB and Abadi AH (2013) Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. *Molecular cancer therapeutics* **12**:1848-1859.

Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W and Snell G (2016b) Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment
associated with neurodegenerative and neuropsychiatric diseases. *Journal of medicinal chemistry* **59**:1149-1164.

Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W, Snell G, Sogabe S, Heyser CJ, Snyder GL, Hendrick JP, Vanover KE, Davis RE and Wennogle LP (2016c) Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. *J Med Chem* **59**:1149-1164.

Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O'Donnell JM and Zhang HT (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **31**:172-183.

Li YJ, Shi JR, Li SC, Wang LM, Dhar R, Li N, Cao XW, Li ZG and Tang HF (2023) Phosphodiesterase type 10A inhibitor attenuates lung fibrosis by targeting myofibroblast activation. *iScience* **26**:106586.

Liang J, Huang YY, Zhou Q, Gao Y, Li Z, Wu D, Yu S, Guo L, Chen Z, Huang L, Liang SH, He X, Wu R and Luo HB (2020) Discovery and Optimization of alpha-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. *Journal of medicinal chemistry* **63**:3370-3380.

Libe R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA and Bertherat J (2008) Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **14**:4016-4024.

Libe R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson ML, Siegel J, Moran J, Drori-Herishanu L, Faucz FR, Lodish M, Nesterova M, Bertagna X, Bertherat J and Stratakis CA (2011) Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. *The Journal of clinical endocrinology and metabolism* **96**:E208-214.

Lin CY, Yu HP, Chang YT, Lin ZC, Alalaiwe A, Hwang TL and Fang JY (2023a) Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via the Ly6 antigen for psoriasiform dermatitis alleviation. *Biomater Sci* **11**:873-893.

Lin TY, Mai QN, Zhang H, Wilson E, Chien HC, Yee SW, Giacomini KM, Olgin JE and Irannejad R (2023b) Cardiac contraction and relaxation are regulated by distinct subcellular cAMP pools. *Nat Chem Biol*.

Lincoln TM and Cornwell TL (1991) Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. *Blood Vessels* **28**:129-137.

Ling SH, McDonough JE, Gosselink JV, Elliott WM, Hayashi S, Hogg JC and van Eeden SF (2011) Patterns of retention of particulate matter in lung tissues of patients with COPD: potential role in disease progression. *Chest* **140**:1540-1549.

Lipina TV, Palomo V, Gil C, Martinez A and Roder JC (2013) Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. *Neuropharmacology* **64**:205-214.

Liu A, Huang L, Wang Z, Luo Z, Mao F, Shan W, Xie J, Lai K and Li X (2013) Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. *Bioorg Med Chem Lett* **23**:1548-1552.

Liu K, Li D, Hao G, McCaffary D, Neely O, Woodward L, Ioannides D, Lu CJ, Brescia M, Zaccolo M, Tandri H, Ajijola OA, Ardell JL, Shivkumar K and Paterson DJ (2018) Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity. *JCI Insight* **3**:pii: 98694.

Liu MC, Hubbard WC, Proud D, Stealey BA, Galli SJ, Kagey-Sobotka A, Bleecker ER and Lichtenstein LM (1991) Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. *Am Rev Respir Dis* **144**:51-58.

Liu S, Zhang J and Xiang YK (2011) FRET-based direct detection of dynamic protein kinase A activity on the sarcoplasmic reticulum in cardiomyocytes. *Biochem Biophys Res Commun* **404**:581-586.
Liu SF, Nambiar Veetil N, Li Q, Kucherenko MM, Knosalla C and Kuebler WM (2022) Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. *Front Immunol* **13**:959209.

Liu X, Sun SQ, Hassid A and Ostrom RS (2006) cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. *Mol Pharmacol* **70**:1992-2003.

Lohse MJ, Bock A and Zaccolo M (2023) G Protein-Coupled Receptor Signaling: New Insights Define Cellular Nanodomains. *Annu Rev Pharmacol Toxicol*.

Lohse MJ, Engelhardt S and Eschenhagen T (2003) What is the role of β-adrenergic signaling in heart failure? *Circ Res* **93**:896-906.

Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL, Jr., Ramond MJ, Maddrey WC, Morgan TR, Duhamel A and Mathurin P (2018) Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. *Gastroenterology* **155**:458-468 e458.

Lueptow LM, Zhan CG and O'Donnell JM (2016) Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice. *Psychopharmacology (Berl)* **233**:447-456.

Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. *Pharmacol Ther* **109**:366-398.

Lugnier C, Keravis T and Eckly-Michel A (1999a) Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. *J Physiol Pharmacol* **50**:639-652.

Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S and Rousseau E (1999b) Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. *Biochim Biophys Acta* **1472**:431-446.

Lugnier C, Muller B, Le Bec A, Beaudry C and Rousseau E (1993) Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. *J Pharmacol Exp Ther* **265**:1142-1151.

Lugnier C and Schini VB (1990) Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. *Biochem Pharmacol* **39**:75-84.

Lugnier C, Schoeffter P, Le Bec A, Strouthou E and Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. *Biochem Pharmacol* **35**:1743-1751.

Luke JJ, Bao R, Sweis RF, Spranger S and Gajewski TF (2019) WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. *Clin Cancer Res* **25**:3074-3083.

Ma J, Kumar V and Mahato RI (2022) Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease. *Pharmaceutics* **14**.

MacMullen CM, Vick K, Pacifico R, Fallahi-Sichani M and Davis RL (2016) Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. *Translational psychiatry* **6**:e742-e742.

Mahmood SU, Lozano Gonzalez M, Tummalapalli S, Eberhard J, Ly J, Hoffman CS, Kelly MP, Gordon J, Colussi D, Childers W and Rotella DP (2023) First Optimization of Novel, Potent, Selective PDE11A4 Inhibitors for Age-Related Cognitive Decline. *Journal of medicinal chemistry* **66**:14597-14608.

Majed BH and Khalil RA (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. *Pharmacol Rev* **64**:540-582.

Majumder S, Tamilarasan KP, Kolluru GK, Muley A, Nair CM, Omanakuttan A, Murty KV and Chatterjee S (2007) Activated pericyte attenuates endothelial functions: nitric oxide-cGMP rescues activated pericyte-associated endothelial dysfunctions. *Biochem Cell Biol* **85**:709-720.

Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, Hawkes CA, Saito S, Yamamoto Y, Terasaki Y, Ishibashi-Ueda H, Taguchi A, Takahashi R, Miyakawa T, Kalaria RN, Lo EH, Arai K and Ihara M (2014)
Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid. *Annals of clinical and translational neurology* **1**:519-533.

Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Ahnen DJ, Thompson H, Pamukcu R and Piazza GA (1998) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). *Carcinogenesis* **19**:1353-1356.

Mallia P and Johnston SL (2006) How viral infections cause exacerbation of airway diseases. *Chest* **130**:1203-1210.

Manabe H, Akuta K, Kawasaki H and Ohmori K (2000) The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs. *Pulm Pharmacol Ther* **13**:5-11.

Manabe H, Akuta K, Sejimo H, Kawasaki H, Nukui E, Ichimura M, Kase H, Kawakita T, Suzuki F, Kitamura S, Sato S and Ohmori K (1997) Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. *Eur J Pharmacol* **332**:97-107.

Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ and Barnette MS (1996) Prolonged β-adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. *Journal of Pharmacology and Experimental Therapeutics* **276**:810-818.

Manolis AA, Manolis TA, Melita H, Mikhailidis DP and Manolis AS (2022) Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. *J Clin Pharmacol* **62**:320-358.

Margelidon-Cozzolino V, Tsicopoulos A, Chenivesse C and de Nadai P (2022) Role of Th17 Cytokines in Airway Remodeling in Asthma and Therapy Perspectives. *Front Allergy* **3**:806391.

Maria GG and Juan GG (2017) Negative Bias in the Perception and Memory of Emotional Information in Alzheimer Disease. *J Geriatr Psychiatry Neurol* **30**:131-139.

Marin N, Zamorano P, Carrasco R, Mujica P, Gonzalez FG, Quezada C, Meininger CJ, Boric MP, Duran WN and Sanchez FA (2012) S-Nitrosation of beta-catenin and p120 catenin: a novel regulatory mechanism in endothelial hyperpermeability. *Circ Res* **111**:553-563.

Marino N, Collins JW, Shen C, Caplen NJ, Merchant AS, Gökmen-Polar Y, Goswami CP, Hoshino T, Qian Y and Sledge GW (2014) Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. *Clinical & experimental metastasis* **31**:771-786.

Marot A, Singal AK, Moreno C and Deltenre P (2020) Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials. *JHEP Rep* **2**:100139.

Martin JG, Duguet A and Eidelman DH (2000) The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease. *Eur Respir J* **16**:349-354.

Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG and Beavo JA (2002) The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. *Proc Natl Acad Sci U S A* **99**:13260-13265.

Martins TJ, Mumby MC and Beavo JA (1982a) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. *J Biol Chem* **257**:1973-1979.

Martins TJ, Mumby MC and Beavo JA (1982b) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. *J Biol Chem* **257**:1973-1979.

Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG and O'Donnell JM (2009) Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. *J Pharmacol Exp Ther* **331**:690-699.

Maurice DH (2013) PDE8A runs interference to limit PKA inhibition of Raf-1. *Proc Natl Acad Sci U S A* **110**:6248-6249.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J and Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. *Nat Rev Drug Discov* **13**:290-314.
McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G and Houslay MD (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. *Cell Signal* **17**:1158-1173.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A and Group ESCSD (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* **24**:4-131.

McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, Paré PD, Sin DD, Pierce RA, Woods JC, McWilliams AM, Mayo JR, Lam SC, Cooper JD and Hogg JC (2011) Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med* **365**:1567-1575.

McGirr A, Lipina TV, Mun HS, Georgiou J, Al-Amri AH, Ng E, Zhai D, Elliott C, Cameron RT, Mullins JG, Liu F, Baillie GS, Clapcote SJ and Roder JC (2016) Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. *Neuropsychopharmacology* **41**:1080-1092.

McLachlan CS, Chen ML, Lynex CN, Goh DL, Brenner S and Tay SK (2007) Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. *Arch Neurol* **64**:456-457.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K and Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* **371**:993-1004.

McQuail JA, Beas BS, Kelly KB, Hernandez CM, 3rd, Bizon JL and Frazier CJ (2021) Attenuated NMDAR signaling on fast-spiking interneurons in prefrontal cortex contributes to age-related decline of cognitive flexibility. *Neuropharmacology* **197**:108720.

McQuown S, Xia S, Baumgartel K, Barido R, Anderson G, Dyck B, Scott R and Peters M (2019) Phosphodiesterase 1b (PDE1B) Regulates Spatial and Contextual Memory in Hippocampus. *Frontiers in molecular neuroscience* **12**:21.

Medzhitov R (2021) The spectrum of inflammatory responses. *Science* **374**:1070-1075.

Mehel H, Emons J, Vettel C, Wittköpper K, Seppelt D, Dewenter M, Lutz S, Sossalla S, Maier LS, Lechêne P, Leroy J, Lefebvre F, Varin A, Eschenhagen T, Nattel S, Dobrev D, Zimmermann W-H, Nikolaev VO, Vandecasteele G, Fischmeister R and El-Armouche A (2013) Phosphodiesterase-2 is upregulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. *J Am Coll Cardiol* **62**:1596-1606.

Mei X-L, Yang Y, Zhang Y-J, Li Y, Zhao J-M, Qiu J-G, Zhang W-J, Jiang Q-W, Xue Y-Q and Zheng D-W (2015) Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. *American journal of cancer research* **5**:3311.

Meizlish ML, Franklin RA, Zhou X and Medzhitov R (2021) Tissue Homeostasis and Inflammation. *Annu Rev Immunol* **39**:557-581.

Meloche J, Renard S, Provencher S and Bonnet S (2013) Anti-inflammatory and immunosuppressive agents in PAH. *Handb Exp Pharmacol* **218**:437-476.

Menniti FS, Chappie TA and Schmidt CJ (2021) PDE10A inhibitors—clinical failure or window into antipsychotic drug action? *Frontiers in Neuroscience* **14**:600178.

Merkle D and Hoffmann R (2011) Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. *Cell Signal* **23**:507-515.

Méry P, Pavoine C, Pecker F and Fischmeister R (1995) Erythro-9-(2-hydroxy-3-nonyl) adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. *Molecular pharmacology* **48**:121-130.
Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-Garcia JA, Alonso-Gil S, Perez-Castillo A, Gil C, Martinez A and Guaza C (2015) PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. *British journal of pharmacology* **172**:4277-4290.

Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J and Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. *Archives of neurology* **56**:1383-1386.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M and Umansky V (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. *Proc Natl Acad Sci USA* **108**:17111-17116.

Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA and Wigler M (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. *J Biol Chem* **268**:12925-12932.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D and Archer SL (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* **108**:2066-2069.

Michie AM, Lobban M, Muller T, Harnett MM and Houslay MD (1996) Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. *Cell Signal* **8**:97-110.

Michie AM, Rena G, Harnett MM and Houslay MD (1998) Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases. *Cell Biochem Biophys 28*:161-185.

Mika D, Bobin P, Lindner M, Boet A, Hodzic A, Lefebvre F, Lechene P, Sadoune M, Samuel JL, Algalarrondo V, Rucker-Martin C, Lambert V, Fischmeister R, Vandecasteele G and Leroy J (2019) Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model. *J Mol Cell Cardiol* **133**:57-66.

Mika D, Bobin P, Pomérance M, Lechêne P, Westenbroek RE, Catterall WA, Vandecasteele G, Leroy J and Fischmeister R (2013) Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes. *Cardiovasc Res* **100**:336-346.

Mika D, Leroy J, Vandecasteele G and Fischmeister R (2012) PDEs create local domains of cAMP signaling. *J Mol Cell Cardiol* **52**:323-329.

Mikami S, Kawasaki M, Ikeda S, Negoro N, Nakamura S, Nomura I, Ashizawa T, Kokubo H, Hoffman ID, Zou H, Oki H, Uchiyama N, Hiura Y, Miyamoto M, Itou Y, Nakashima M, Iwashita H and Taniguchi T (2017a) Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders. *Chemical & pharmaceutical bulletin* **65**:1058-1077.

Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H and Taniguchi T (2017b) Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. *Journal of medicinal chemistry* **60**:7677-7702.

Mikami S, Sasaki S, Asano Y, Ujikawa O, Fukumoto S, Nakashima K, Oki H, Kamiguchi N, Imada H, Iwashita H and Taniguchi T (2017c) Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders. *Journal of medicinal chemistry* **60**:7658-7676.

Milakovic M and Gooderham MJ (2021) Phosphodiesterase-4 Inhibition in Psoriasis. *Psoriasis (Auckl)* **11**:21-29.
Milara J, Armengot M, Banuls P, Tenor H, Beume R, Artigues E and Cortijo J (2012) Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. *Br J Pharmacol* **166**:2243-2262.

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH and Haining WN (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat Immunol* **20**:326-336.

Miller CL, Cai Y, Oikawa M, Thomas T, Dostmann WR, Zaccolo M, Fujiwara K and Yan C (2011) Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. *Basic Res Cardiol* **106**:1023-1039.

Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J and Yan C (2009a) Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. *CircRes* **105**:956-964.

Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J and Yan C (2009b) Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. *Circ Res* **105**:956-964.

Miller S, Hill Della Puppa G, Reidling J, Marcora E, Thompson LM and Treanor J (2014) Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. *Journal of Huntington's disease* **3**:333-341.

Mirabello L, Kratz CP, Savage SA and Greene MH (2012) Promoter methylation of candidate genes associated with familial testicular cancer. *International journal of molecular epidemiology and genetics* **3**:213-227.

Miravitlles M, Soler-Cataluña JJ, Calle M and Soriano JB (2013) Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. *Eur Respir J* **41**:1252-1256.

Mirza S, Clay RD, Koslow MA and Scanlon PD (2018) COPD Guidelines: A Review of the 2018 GOLD Report. *Mayo Clin Proc* **93**:1488-1502.

Mishra S, Sadagopan N, Dunkerly-Eyring B, Rodriguez S, Sarver DC, Ceddia RP, Murphy SA, Knutsdottir H, Jani VP, Ashok D, Oeing CU, O'Rourke B, Gangoiti JA, Sears DD, Wong GW, Collins S and Kass DA (2021) Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. *J Clin Invest* **131**.

Mochizuki Y, Oishi M and Mizutani T (2001) Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* **10**:63-69.

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Tasken KA and Skalhegg BS (2017) Observed correlation between the expression levels of catalytic subunit, Cbeta2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness. *Urol Oncol* **35**:111 e111-111 e118.

Molina-Arcas M, Samani A and Downward J (2021) Drugging the Undruggable: Advances on RAS Targeting in Cancer. *Genes (Basel)* **12**.

Molina CE, Leroy J, Xie M, Richter W, Lee I-O, Maack C, Rucker-Martin C, Donzeau-Gouge P, Verde I, Hove-Madsen L, Barriga M, Conti M, Vandecasteele G and Fischmeister R (2012) Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. *J Am Coll Cardiol* **59**:2182-2190.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jais X, Humbert M, Simonneau G and Sitbon O (2009) Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. *Adv Ther* **26**:813-825.

Montani D, Seferian A, Savale L, Simonneau G and Humbert M (2013) Drug-induced pulmonary arterial hypertension: a recent outbreak. *Eur Respir Rev* **22**:244-250.
Monterisi S, Lobo MJ, Livie C, Castle JC, Weinberger M, Baillie GS, Surdo NC, Musheshe N, Stangherlin A, Gottlieb E, Maizels RJ, Bortolozzi M, Micaroni M and Zaccolo M (2017) PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling. *Elife* 6:e21374.

Montoya-Durango D, Walter MN, Rodriguez W, Wang Y, Chariker JH, Rouchka EC, Maldonado C, Barve S, McClain CJ and Gobejishvili L (2023) Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies. *Biology (Basel)* **12**.

Monville C, Torres EM and Dunnett SB (2005) Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. *Brain research bulletin* **68**:16-23.

Moodley T, Wilson SM, Joshi T, Rider CF, Sharma P, Yan D, Newton R and Giembycz MA (2013) Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. *Mol Pharmacol* **83**:894-906.

Moon E, Lee R, Near R, Weintraub L, Wolda S and Lerner A (2002) Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. *Clin Cancer Res* **8**:589-595.

Morales-Garcia JA, Aguilar-Morante D, Hernandez-Encinas E, Alonso-Gil S, Gil C, Martinez A, Santos A and Perez-Castillo A (2015a) Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. *Neurobiology of aging* **36**:1160-1173.

Morales-Garcia JA, Alonso-Gil S, Gil C, Martinez A, Santos A and Perez-Castillo A (2015b) Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. *Stem cells translational medicine* **4**:564-575.

Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, Sanz-SanCristobal M, Lopez-Moreno JA, Gil C, Martinez A, Santos A and Perez-Castillo A (2017) Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. *Stem cells* **35**:458-472.

Morales-Garcia JA, Palomo V, Redondo M, Alonso-Gil S, Gil C, Martinez A and Perez-Castillo A (2014) Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. *ACS chemical neuroscience* **5**:194-204.

Mori F, Pérez-Torres S, De Caro R, Porzionato A, Macchi V, Beleta J, Gavaldà A, Palacios JM and Mengod G (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. *Journal of chemical neuroanatomy* **40**:36-42.

Morphy R and Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. *J Med Chem* **48**:6523-6543.

Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, Trembath RC and Loyd JE (2019) Genetics and genomics of pulmonary arterial hypertension. *Eur Respir J* **53**.

Mosenden R and Tasken K (2011) Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. *Cell Signal* **23**:1009-1016.

Mostafa MM, Rider CF, Wathugala ND, Leigh R, Giembycz MA and Newton R (2021) Transcriptome-level interactions between budesonide and formoterol provide insight into the mechanism of action of inhaled corticosteroid/long-acting β₂-adrenoceptor agonist combination therapy in asthma. *Mol Pharmacol* **99**:197-216.

Movsesian M, Wever-Pinzon O and Vandeput F (2011) PDE3 inhibition in dilated cardiomyopathy. *Curr Opin Pharmacol* **11**:707-713.

Movsesian MA (2003a) PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. *J Card Fail* **9**:475-480.

Movsesian MA (2003b) PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. *Journal of cardiac failure* **9**:475-480.
Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P, Romero-Clavijo P, Valand K, Cole M, Molina-Arcas M and Downward J (2022) Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. *Sci Adv* **8:eabm8780.**

Muller GK, Song J, Jani V, Wu Y, Liu T, Jeffreys WPD, O'Rourke B, Anderson ME and Kass DA (2021) PDE1 Inhibition Modulates Ca(v)1.2 Channel to Stimulate Cardiomyocyte Contraction. *Circ Res* **129**:872-886.

Muñoz NM, Rabe KF, Vita AJ, McAllister K, Mayer D, Weiss M and Leff AR (1995) Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. *J Pharmacol Exp Ther* **273**:850-854.

Muraki Y, Naito T, Tohyama K, Shibata S, Kuniyeda K, Nio Y, Hazama M and Matsuo T (2019) Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension. *Biosci Biotechnol Biochem* **83**:1000-1010.

Murray F, MacLean MR and Pyne NJ (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. *Br J Pharmacol* **137**:1187-1194.

Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX and Insel PA (2007) Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. *Am J Physiol Lung Cell Mol Physiol* **292**:L294-303.

Myou S, Fujimura M, Kamio Y, Hirose T, Kita T, Tachibana H, Ishiura Y, Watanabe K, Hashimoto T and Nakao S (2003) Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. *Br J Clin Pharmacol* **55**:341-346.

Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T and Matsuda T (1999) Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. *Am J Respir Crit Care Med* **160**:817-820.

Naeije R (2003) Pulmonary hypertension and right heart failure in COPD. *Monaldi Arch Chest Dis* **59**:250-253.

Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T, Nagumo H, Kodama T, Takemura M, Ohtsuka Y, Nakamura J, Tsujita R, Kawasaki K, Yokoi H and Kawanishi M (2009) Discovery of selective PDE4B inhibitors. *Bioorg Med Chem Lett* **19**:3174-3176.

Nagayama T, Zhang M, Hsu S, Takimoto E and Kass DA (2008) Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. *J Pharmacol Exp Ther* **326**:380-387.

Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov VA, Berk BC and Yan C (2006) Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. *Circ Res* **98**:777-784.

Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR and Michelakis ED (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. *Circulation* **116**:238-248.

Nakamura T, Ranek MJ, Lee DI, Shalkey Hahn V, Kim C, Eaton P and Kass DA (2015) Prevention of PKG1alpha oxidation augments cardioprotection in the stressed heart. *J Clin Invest* **125**:2468-2472.

Nakamura T, Zhu G, Ranek MJ, Kokkonen-Simon K, Zhang M, Kim GE, Tsujita K and Kass DA (2018a) Prevention of PKG-1alpha Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. *Circ Heart Fail* **11:e004740.**

Nakamura T, Zhu G, Ranek MJ, Kokkonen-Simon K, Zhang M, Kim GE, Tsujita K and Kass DA (2018b) Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. *Circ Heart Fail* **11:e004740.**
Nakashima M, Suzuki N, Shiraishi E and Iwashita H (2019) TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models. *Behavioural brain research* **376**:112192.

Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K and Kaminuma O (2002) Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. *Clin Exp Immunol* **128**:460-466.

Nakata TM, Suzuki K, Uemura A, Shimada K and Tanaka R (2019) Contrasting effects of inhibition of phosphodiesterase 3 and 5 on cardiac function and interstitial fibrosis in rats with isoproterenol-induced cardiac dysfunction. *J Cardiovasc Pharmacol* **73**:195-205.

Napolitano M, Marasca C, Fabbrocini G and Patruno C (2018) Adult atopic dermatitis: new and emerging therapies. *Expert Rev Clin Pharmacol* **11**:867-878.

Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C and Narayanan NK (2007) Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. *Clin Cancer Res* **13**:5965-5973.

Nazareth LV and Weigel NL (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. *J Biol Chem* **271**:19900-19907.

Nazir S, Anwar F, Saleem U, Ahmad B, Raza Z, Sanawar M, Rehman AU and Ismail T (2021) Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice. *Neurochemical research* **46**:1814-1829.

Netherton SJ and Maurice DH (2005) Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. *Mol Pharmacol* **67**:263-272.

Netherton SJ, Sutton JA, Wilson LS, Carter RL and Maurice DH (2007) Both protein kinase A and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. *Circ Res* **101**:768-776.

Newton R (2014) Anti-inflammatory glucocorticoids: changing concepts. *Eur J Pharmacol* **724**:231-236.

Newton R and Giembycz MA (2016) Understanding how long-acting β₂-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update. *Br J Pharmacol* **173**:3405-3430.

Ni L, Chuang CC and Zuo L (2015) Fine particulate matter in acute exacerbation of COPD. *Front Physiol* **6**:294.

Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE and Knowles RG (2011) In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. *J Pharmacol Exp Ther* **337**:137-144.

Nikolaev VO, Bunemann M, Hein L, Hannawacker A and Lohse MJ (2004) Novel single chain cAMP sensors for receptor-induced signal propagation. *J Biol Chem* **279**:37215-37218.

Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE and Gorelik J (2010) β₂-Adrenergic receptor redistribution in heart failure changes cAMP compartmentation. *Science* **327**:1653-1657.

Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N and Greengard P (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. *Journal of Neuroscience* **28**:10460-10471.

Nishida M, Watanabe K, Sato Y, Nakaya M, Kitajima N, Ide T, Inoue R and Kurose H (2010) Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. *JBiolChem* **285**:13244-13253.

Nueda A, Garcia-Roger N, Domenech T, Godessart N, Cardenas A, Santamaria-Babi LF and Beleta J (2006) Phosphodiesterase 7A1 is expressed in human CD4+ naive T cells at higher levels than in CD4+ memory cells and is not required during their CD3/CD28-dependent activation. *Cell Immunol* **242**:31-38.

Numata G and Takimoto E (2022) Cyclic GMP and PKG signaling in heart failure. *Front Pharmacol* **13**:792798.
Nutt MDJG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. *Neurology* **40**:340-340.

O'Brien JJ, O'Callaghan JP, Miller DB, Chalgeri S, Wennogle LP, Davis RE, Snyder GL and Hendrick JP (2020) Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses. *Mol Cell Neurosci* **102**:103449.

Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, Ujikawa O, Shimokawa K, Sano O, Koyama R, Fujita H, Teratani M, Matsumoto H, Imaeda Y, Nara H, Cho N and Naito M (2017) In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). *J Biol Chem* **292**:4556-4570.

Oikawa M, Wu M, Lim S, Knight WE, Miller CL, Cai Y, Lu Y, Blaxall BC, Takeishi Y, Abe JI and Yan C (2013) Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. *J Mol Cell Cardiol* **64**:11-19.

Oki NO, Motsinger-Reif AA, Antas PR, Levy S, Holland SM and Sterling TR (2011) Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. *BMC research notes* **4**:28.

Olanow CW (2009) Can we achieve neuroprotection with currently available anti-parkinsonian interventions? *Neurology* **72**:S59-S64.

Omar F, Findlay JE, Carfray G, Allcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, Day JP, Bolger G, Baillie GS, Schwiebert E, Klussmann E, Pyne NJ, Ong ACM, Bowers K, Adam JM, Adams DR, Houslay MD and Henderson DJP (2019) Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. *Proc Natl Acad Sci U S A* **116**:13320-13329.

Orejana L, Barros-Minones L, Jordan J, Puerta E and Aguirre N (2012) Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. *Neurobiology of aging* **33**:625 e611-620.

Orlowski RJ, O'Rourke KS, Olorenshaw J, Hawkins GA, Maas S and Laxminarayana D (2008) Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes. *Immunology* **125**:408-419.

Ortiz JL, Dasí FJ, Cortijo J and Morcillo EJ (2000) β–Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E₂-inhibitory effects in human neutrophils. *Naunyn-Schmiedeberg's archives of pharmacology* **361**:410-417.

Ostrem JM, Peters U, Sos ML, Wells JA and Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature* **503**:548-551.

Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML and et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med* **325**:1468-1475.

Paes D, Lardenoije R, Carollo RM, Roubroeks JAY, Schepers M, Coleman P, Mastroeni D, Delvaux E, Pishva E, Lunnon K, Vanmierlo T, van den Hove D and Prickaerts J (2021a) Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer's disease. *Neurobiol Aging* **97**:56-64.

Paes D, Schepers M, Rombaut B, van den Hove D, Vanmierlo T and Prickaerts J (2021b) The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors. *Pharmacol Rev* **73**:1016-1049.

Paes D, Schepers M, Willems E, Rombaut B, Tiane A, Solomina Y, Tibbo A, Blair C, Kyurkchieva E, Baillie GS, Ricciarelli R, Brullo C, Fedele E, Bruno O, van den Hove D, Vanmierlo T and Prickaerts J (2023) Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-beta pathology. *Cell Mol Life Sci* **80**:178.

Palmer D, Jimmo SL, Raymond DR, Wilson LS, Carter RL and Maurice DH (2007) Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. *J Biol Chem* **282**:9411-9419.

Palmeri A, Privitera L, Giunta S, Loreto C and Puzzo D (2013) Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. *Behavioural brain research* **240**:11-20.
Pan JB, Hou YH and Zhang GJ (2009) Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats. *Respirology* **14**:975-982.

Pandit J, Forman MD, Fennell KF, Dillman KS and Menniti FS (2009) Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. *Proc Natl Acad Sci U S A* **106**:18225-18230.

Patel NS, Klett J, Pilarzyk K, Lee DI, Kass D, Menniti FS and Kelly MP (2018) Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span. *Neurobiol Aging* **65**:217-234.

Pathak A, Stewart DR, Faucz FR, Xekouki P, Bass S, Vogt A, Zhang X, Boland J, Yeager M, Loud JT, Nathanson KL, McGlynn KA, Stratakis CA, Greene MH and Mirabello L (2015) Rare inactivating PDE11A variants associated with testicular germ cell tumors. *Endocrine-related cancer* **22**:909-917.

Pathak G, Agostino MJ, Bishara K, Capell WR, Fisher JL, Hegde S, Ibrahim BA, Pilarzyk K, Sabin C, Tuczkewycz T, Wilson S and Kelly MP (2016) PDE11A negatively regulates lithium responsivity. *Molecular psychiatry*.

Pathak G, Agostino MJ, Bishara K, Capell WR, Fisher JL, Hegde S, Ibrahim BA, Pilarzyk K, Sabin C, Tuczkewycz T, Wilson S and Kelly MP (2017) PDE11A negatively regulates lithium responsivity. *Molecular psychiatry* **22**:1714-1724.

Patrucco E, Albergine MS, Santana LF and Beavo JA (2010) Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. *J Mol Cell Cardiol* **49**:330-333.

Pauls MM, Fish J, Binnie LR, Benjamin P, Betteridge S, Clarke B, Dhillon MK, Ghatala R, Hainsworth FA, Howe FA, Khan U, Kruuse C, Madigan JB, Moynihan B, Patel B, Pereira AC, Rostrup E, Shtaya AB, Spilling CA, Trippier S, Williams R, Young R, Barrick TR, Isaacs JD and Hainsworth AH (2023) Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial. *Cereb Circ Cogn Behav* **5**:100187.

Pavlos NJ and Friedman PA (2017) GPCR Signaling and Trafficking: The Long and Short of It. *Trends Endocrinol Metab* **28**:213-226.

Pearse DD and Hughes ZA (2016) PDE4B as a microglia target to reduce neuroinflammation. *Glia* **64**:1698-1709.

Pekcec A, Schulert N, Stierstorfer B, Deiana S, Dorner-Ciossek C and Rosenbrock H (2018a) Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. *British journal of pharmacology* **175**:3021-3033.

Pekcec A, Schülert N, Stierstorfer B, Deiana S, Dorner-Ciossek C and Rosenbrock H (2018b) Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. *British journal of pharmacology* **175**:3021-3033.

Pekkinen M, Ahlstrom MEB, Riehle U, Huttunen MM and Lamberg-Allardt CJE (2008) Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. *Bone* **43**:84-91.

Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB, Sr., Peterson ED and Sniderman AD (2019) Quantifying Importance of Major Risk Factors for Coronary Heart Disease. *Circulation* **139**:1603-1611.

Pendin D, Greotti E, Lefkimmiatis K and Pozzan T (2017) Exploring cells with targeted biosensors. *J Gen Physiol* **149**:1-36.

Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, Yue J, Bahouth SW, Buddington RK, Zhang G, Nelson DJ, Sonecha MD, Manganiello V, Wine JJ and Naren AP (2010) Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. *Molecular biology of the cell* **21**:1097-1110.

Pepke-Zaba J, Ghofrani HA and Hoeper MM (2017) Medical management of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev* **26**.
Pepke-Zaba J, Gilbert C, Collings L and Brown MC (2008) Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. *Chest* **133**:183-189.

Perera RK, Sprenger JU, Steinbrecher JH, Hubscher D, Lehnart SE, Abesser M, Schuh K, El-Armouche A and Nikolaev VO (2015) Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac hypertrophy. *Circ Res* **116**:1304-1311.

Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Perez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A and Carro E (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. *Neurobiology of aging* **34**:2133-2145.

Perez-Torres S, Cortes R, Tolnay M, Probst A, Palacios JM and Mengod G (2003) Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. *Experimental neurology* **182**:322-334.

Perez-Torres S and Mengod G (2003) cAMP-specific phosphodiesterases expression in Alzheimer's disease brains. *International Congress Series* **1251**:127-138.

Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdomènech P and Mengod G (2000) Phosphodiesterase type 4 isozymes expression in human brain examined by *in situ* hybridization histochemistry and [³H]rolipram binding autoradiography. Comparison with monkey and rat brain. *Journal of chemical neuroanatomy* **20**:349-374.

Peter D, Jin SL, Conti M, Hatzelmann A and Zitt C (2007) Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. *J Immunol* **178**:4820-4831.

Petraina A, Nogales C, Krahn T, Mucke H, Luscher TF, Fischmeister R, Kass DA, Burnett JC, Hobbs AJ and Schmidt H (2022) Cyclic GMP modulating drugs in cardiovascular diseases: Mechanism-based network pharmacology. *Cardiovasc Res* **118**:2085-2102.

Pette M, Muraro PA, Pette DF, Dinter H, McFarland HF and Martin R (1999) Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. *J Neuroimmunol* **98**:147-156.

Peverelli E, Ermetici F, Filopanti M, Elli FM, Ronchi CL, Mantovani G, Ferrero S, Bosari S, Beck-Peccoz P, Lania A and Spada A (2009) Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients. *European journal of endocrinology / European Federation of Endocrine Societies* **161**:687-694.

Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR and Ferrara N (2013) Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. *Proc Natl Acad Sci U S A* **110**:6079-6084.

Philips CA, Ahamed R, Rajesh S, Singh S, Tharakan A, Abduljaleel JK and Augustine P (2022) Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala. *Gastroenterol Rep (Oxf)* **10**:goac074.

Phillips G and Salmon M (2012) Bifunctional compounds for the treatment of COPD. *Ann Rev Med Chem* **47**:209-221.

Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ and Pamukcu R (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. *Cancer Res* **57**:2909-2915.

Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY and Reynolds RC (2009) A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. *Cancer Prev Res (Phila)* **2**:572-580.
Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE, Jr., Klein-Szanto AJ, Farnell DR, Eto I and Grubbs CJ (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. *Cancer Res* **61**:3961-3968.

Picconi B, Bagetta V, Ghiglieri V, Paille V, Di Filippo M, Pendolino V, Tozzi A, Giampa C, Fusco FR and Sgobio C (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. *Brain* **134**:375-387.

Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, Cenci MA and Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. *Nature neuroscience* **6**:501-506.

Pilarzyk K, Capell WR, Porcher L, Rips-Goodwin A and Kelly MP (2023) Biologic that disrupts PDE11A4 homodimerization in hippocampus CA1 reverses age-related cognitive decline of social memories in mice. *Neurobiology of aging*.

Pilarzyk K, Farmer R, Porcher L and Kelly MP (2021) The Role of PDE11A4 in Social Isolation-Induced Changes in Intracellular Signaling and Neuroinflammation. *Frontiers in pharmacology* **12**:749628.

Pilarzyk K, Klett J, Pena EA, Porcher L, Smith AJ and Kelly MP (2019) Loss of Function of Phosphodiesterase 11A4 Shows that Recent and Remote Long-Term Memories Can Be Uncoupled. *Current biology* : CB **29**:2307-2321 e2305.

Pilarzyk K, Porcher L, Capell WR, Burbano SD, Davis J, Fisher JL, Gorny N, Petrolle S and Kelly MP (2022) Conserved age-related increases in hippocampal PDE11A4 cause unexpected proteinopathies and cognitive decline of social associative memories. *Aging cell* **21**:e13687.

Podzuweit T, Nennstiel P and Müller A (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. *Cellular signalling* **7**:733-738.

Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, Lenzi A, Naro F, Isidori AM and Venneri MA (2017) Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. *Sci Rep* **7**:44584.

Pokreisz P, Vandenwijngaert S, Bito V, Van den BA, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD and Janssens SP (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. *Circulation* **119**:408-416.

Polich J and Gloria R (2001) Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. *Human psychopharmacology* **16**:409-416.

Polidovitch N, Yang S, Sun H, Lakin R, Ahmad F, Gao X, Turnbull PC, Chiarello C, Perry CGR, Manganiello V, Yang P and Backx PH (2019) Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload. *J Mol Cell Cardiol* **132**:60-70.

Polli JW and Kincaid RL (1994) Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. *Journal of Neuroscience* **14**:1251-1261.

Ponsioen B, Zhao J, Riedl J, Zwartkruis FJ, van der Krogt G, Zaccolo M, Moolenaar WH, Bos JL and Jalink K (2004) Detecting cAMP-induced activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. *EMBO Rep* **5**:1-5.

Porcher L, Bruckmeier S, Burbano SD, Finnell JE, Gorny N, Klett J, Wood SK and Kelly MP (2021) Aging triggers an upregulation of a multitude of cytokines in the male and especially the female rodent hippocampus but more discrete changes in other brain regions. *Journal of neuroinflammation* **18**:219.
Postma DS and Kerstjens HA (1998) Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **158**:S187-192.

Postma DS and Timens W (2006) Remodeling in asthma and chronic obstructive pulmonary disease. *Proc Am Thorac Soc* **3**:434-439.

Pozuelo Rubio M, Campbell DG, Morrice NA and Mackintosh C (2005) Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. *Biochem J* **392**:163-172.

Preedy MEJ (2020) Cardiac cyclic nucleotide phosphodiesterases: Roles and therapeutic potential in heart failure. *Cardiovasc Drugs Ther* **34**:401-417.

Prickaerts J, Heckman PRA and Blokland A (2017) Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. *Expert opinion on investigational drugs* **26**:1033-1048.

Provins L, Christophe B, Danhaive P, Dulieu J, Durieu V, Gillard M, Lebon F, Lengelé S, Quéré L and van Keulen B (2006) First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. *Bioorg Med Chem Lett* **16**:1834-1839.

Provins L, Christophe B, Danhaive P, Dulieu J, Gillard M, Quéré L and Stebbins K (2007) Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. *Bioorg Med Chem Lett* **17**:3077-3080.

Pugh EN and Lamb TD (2000) Phototransduction in vertebrate rods and cones: molecular mechanisms of amplification, recovery and light adaptation, in *Molecular Mechanisms in Visual Transduction* (Stavenga DG, DeGrip WJ and Pugh EN eds) pp 183-255, Elsevier Science B.V., New York.

Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC and Stenmark KR (2015) The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. *Am J Physiol Lung Cell Mol Physiol* **308**:L229-252.

Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF and Esteva FJ (2003a) Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. *Journal of clinical oncology* **21**:3454-3461.

Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL and Hortobagyi GN (2003b) Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. *J Clin Oncol* **21**:3454-3461.

Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda MV, Arancio O and Palmeri A (2014) Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. *Neurobiology of aging* **35**:520-531.

Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DW and Arancio O (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **29**:8075-8086.

Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G and Bar-Sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. *Cancer Cell* **21**:836-847.

Qin N, Pittler SJ and Baehr W (1992) In vitro isoprenylation and membrane association of mouse rod photoreceptor cGMP phosphodiesterase alpha and beta subunits expressed in bacteria. *Journal of Biological Chemistry* **267**:8458-8463.

Qiu X, Huang Y, Wu D, Mao F, Zhu J, Yan W, Luo HB and Li J (2018) Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation. *Bioorg Med Chem* **26**:119-133.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Jr., Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH,
Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ and Feng FY (2018) Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* **174**:758-769 e759.

Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. *Br J Pharmacol* **163**:53-67.

Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D and Bethke TD (2005) Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* **366**:563-571.

Rabe KF, Giembycz MA, Dent G, Perkins RS, Evans P and Barnes PJ (1993) Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. *European journal of pharmacology* **231**:305-308.

Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC and Collard HR (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. *Lancet Respir Med* **2**:566-572.

Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M and Wilson KC (2022) Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* **205**:e18-e47.

Raker VK, Becker C and Steinbrink K (2016) The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. *Front Immunol* **7**:123.

Rall TW and Sutherland EW (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. *J Biol Chem* **232**:1065-1076.

Ramos BP, Birnbaum SG, Lindenmayer I, Newton SS, Duman RS and Arnsten AF (2003) Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. [see comment]. *Neuron* **40**:835-845.

Ranek MJ, Kokkonen-Simon KM, Chen A, Dunkerly-Eyring BL, Vera MP, Oeing CU, Patel CH, Nakamura T, Zhu G, Bedja D, Sasaki M, Holewinski RJ, Van Eyk JE, Powell JD, Lee DI and Kass DA (2019) PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. *Nature* **566**:264-269.

Ranek MJ, Oeing C, Sanchez-Hodge R, Kokkonen-Simon KM, Dillard D, Aslam MI, Rainer PP, Mishra S, Dunkerly-Eyring B, Holewinski RJ, Virus C, Zhang H, Mannion MM, Agrawal V, Hahn V, Lee DI, Sasaki M, Van Eyk JE, Willis MS, Page RC, Schisler JC and Kass DA (2020) CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury. *Nat Commun* **11**:5237.

Rangarajan PN, Umesono K and Evans RM (1992) Modulation of glucocorticoid receptor function by protein kinase A. *Mol Endocrinol* **6**:1451-1457.

Rappaport JA and Waldman SA (2020) An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. *Expert Rev Clin Pharmacol* **13**:1125-1137.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE and Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. *New England Journal of Medicine* **342**:1484-1491.

Rashid A (2005) The efficacy and safety of PDE5 inhibitors. *Clin Cornerstone* **7**:47-56.

Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR and Ahsan F (2017) Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). *J Control Release* **250**:96-106.

Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Ledinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J and Traudtner K (2014) Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* **12**:1724-1730 e1725.
Real J, Serna MC, Giner-Soriano M, Fores R, Pera G, Ribes E, Alzamora M, Marsal JR, Heras A and Morros R (2018) Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. *BMC Cardiovasc Disord* **18**:85.

Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, Cruz AA, Fleming L, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Pedersen SE, Sheikh A, Yorgancioglu A and Boulet LP (2019) GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. *European Respiratory Journal* **53**:1901046.

Reddy AT, Lakshmi SP, Banno A and Reddy RC (2020) Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD. *Int J Chron Obstruct Pulmon Dis* **15**:125-134.

Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ and Rao CV (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. *Cancer Res* **59**:3387-3391.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM and Braunwald E (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* **309**:1268-1277.

Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, Morales-Garcia JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid MI, Loza MI, Perez-Castillo A, Mengod G, Campillo NE, Martinez A and Gil C (2012) Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. *Journal of medicinal chemistry* **55**:3274-3284.

Reed TM, Repaske DR, Snyder GL, Greengard P and Vorhees CV (2002a) Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. *Journal of Neuroscience* **22**:5188-5197.

Reed TM, Repaske DR, Snyder GL, Greengard P and Vorhees CV (2002b) Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **22**:5188-5197.

Reeves ML, Leigh BK and England PJ (1987) The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. *Biochemical Journal* **241**:535-541.

Ren L, Yang C, Dou Y, Zhan R, Sun Y and Yu Y (2017) MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A. *Exp Lung Res* **43**:249-258.

Reneerkens OA, Sambeth A, Ramaekers JG, Steinbusch HW, Blokland A and Prickaerts J (2013a) The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study. *Journal of psychopharmacology* **27**:600-608.

Reneerkens OA, Sambeth A, Van Duinen MA, Blokland A, Steinbusch HW and Prickaerts J (2013b) The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. *Psychopharmacology* **225**:303-312.

Rennard S, Knobil K, Rabe KF, Morris A, Schachter N, Locantore N, Canonica WG, Zhu Y and Barnhart F (2008) The efficacy and safety of cilomilast in COPD. *Drugs* **68 Suppl 2**:3-57.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D and Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. *Respiratory research* **12**:18.

Rentsendorj O, Mirzapoiazova T, Adyshev D, Servinsky LE, Renne T, Verin AD and Pearse DB (2008) Role of vasodilator-stimulated phosphoprotein in cGMP-mediated protection of human pulmonary artery endothelial barrier function. *Am J Physiol Lung Cell Mol Physiol* **294**:L686-697.
Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G and de Vente J (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. *The European journal of neuroscience* **25**:3332-3338.

Reyes-Irisarri E, Pérez-Torres S and Mengod G (2005) Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. *Neuroscience* **132**:1173-1185.

Ribaudo G, Memo M and Gianoncelli A (2021) A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration. *Pharmaceuticals (Basel)* **14**.

Ricciarelli R, Brullo C, Prickaerts J, Arancio O, Villa C, Rebosio C, Calcagno E, Balbi M, van Hagen BT, Argyrousi EK, Zhang H, Pronzato MA, Bruno O and Fedele E (2017) Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. *Sci Rep* **7**:46320.

Rich NE (2024) Changing Epidemiology of Hepatocellular Carcinoma Within the United States and Worldwide. *Surg Oncol Clin N Am* **33**:1-12.

Richards M, Lomas O, Jalink K, Ford KL, Vaughan-Jones RD, Lefkimmiatis K and Swietach P (2016) Intracellular tortuosity underlies slow cAMP diffusion in adult ventricular myocytes. *Cardiovasc Res* **110**:395-407.

Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM and Trial I (2022) Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. *N Engl J Med* **386**:2178-2187.

Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M and Tabaj G (2018) Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. *Eur Respir Rev* **27**.

Richter W, Day P, Agrawal R, Bruss MD, Granier S, Wang YL, Rasmussen SG, Horner K, Wang P, Lei T, Patterson AJ, Kobilka B and Conti M (2008) Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. *The EMBO journal* **27**:384-393.

Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA and Conti M (2011a) Conserved expression and functions of PDE4 in rodent and human heart. *Basic Res Cardiol* **106**:249-262.

Richter Y, Herzog Y, Eyal I and Cohen T (2011b) Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial. *Journal of dietary supplements* **8**:158-168.

Rider CF, Altonsy MO, Mostafa MM, Shah SV, Sasse S, Manson ML, Yan D, Karrman-Mardh C, Miller-Larsson A, Gerber AN, Giembycz MA and Newton R (2018) Long-acting β₂-adrenoceptor agonists enhance glucocorticoid receptor (GR)-mediated transcription by gene-specific mechanisms rather than generic effects via GR. *Mol Pharmacol* **94**:1031-1046.

Rizzi A, Amari G, Pivetti F, Delcanale M, Amadei F, Pappani A, Fornasari L, Villetti G, Marchini G, Pisano AR, Pitozzi V, Pittelli MG, Trevisani M, Salvadori M, Cenacchi V, Fioni A, Puccini P, Civelli M, Patacchini R, Baker-Glenn C, Van de Poël H, Blackaby W, Nash K and Armani E (2023) Optimization of M₃ antagonist-PDE4 inhibitor (MAPI) dual pharmacology molecules for the treatment of COPD. *Journal of medicinal chemistry* **66**:11476-11497.

Robichaud A, Savoie C, Stamatiou PB, Tattersall FD and Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. *Neuropharmacology* **40**:262-269.

Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M and Chan CC (2002) Deletion of phosphodiesterase 4D in mice shortens α₂-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. *Journal of Clinical Investigation* **110**:1045-1052.

Robichaud A, Tattersall FD, Choudhury I and Rodger IW (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. *Neuropharmacology* **38**:289-297.

Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A and Polson JB (1991) Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. *Biochem Pharmacol* **42**:869-877.

Robicsek SA, Krzanowski JJ, Szentivanyi A and Polson JB (1989) High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. *Biochem Biophys Res Commun* **163**:554-560.
Rodriguez WE, Wahlang B, Wang Y, Zhang J, Vadhanam MV, Joshi-Barve S, Bauer P, Cannon R, Ahmadi AR, Sun Z, Cameron A, Barve S, Maldonado C, McClain C and Gobejishvili L (2019) Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench. *Hepatology* **70**:1958-1971.

Roffel AF, Meurs H, Elzinga CR and Zaagsma J (1995) No evidence for a role of muscarinic M2 receptors in functional antagonism in bovine trachea. *Br J Pharmacol* **115**:665-671.

Roks AJM (2022) Phosphodiesterase-1 in the cardiovascular system. *Cell Signal* **92**:110251.

Rosenbrock H, Giovannini R, Schanzle G, Koros E, Runge F, Fuchs H, Marti A, Reymann KG, Schroder UH, Fedele E and Dorner-Ciossek C (2019) The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents. *The Journal of pharmacology and experimental therapeutics* **371**:633-641.

Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A and Vachieri JL (2016) Left ventricular heart failure and pulmonary hypertension. *Eur Heart J* **37**:942-954.

Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K and Loughney K (1997) Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. *Gene* **191**:89-95.

Ruan L, Du K, Tao M, Shan C, Ye R, Tang Y, Pan H, Lv J, Zhang M and Pan J (2019) Phosphodiesterase-2 Inhibitor Bay 60-7550 Ameliorates Abeta-Induced Cognitive and Memory Impairment via Regulation of the HPA Axis. *Frontiers in cellular neuroscience* **13**:432.

Rueda CM, Jackson CM and Chougnet CA (2016) Regulatory T-Cell-Mediated Suppression of Conventional T-Cells and Dendritic Cells by Different cAMP Intracellular Pathways. *Front Immunol* **7**:216.

Ruopp NF and Cockrill BA (2022) Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. *JAMA* **327**:1379-1391.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP and Marek KL (2014) The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. *JAMA neurology* **71**:1520-1528.

Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caille F, Alagille D, Morley TJ, Papin C, Seibyl JP and Marek KL (2016) Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. *Neurology* **86**:748-754.

Russell JA (1984) Differential inhibitory effect of isoproterenol on contractions of canine airways. *J Appl Physiol Respir Environ Exerc Physiol* **57**:801-807.

Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L and Wallace TL (2008) Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. *The European journal of neuroscience* **28**:625-632.

Rutten K, Wallace TL, Works M, Prickaerts J, Blokland A, Novak TJ, Santarelli L and Misner DL (2011) Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice. *Neuropharmacology* **61**:138-147.

Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH and Wren PB (2014) GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. *The Journal of pharmacology and experimental therapeutics* **350**:153-163.

Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG and Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. *J Clin Invest* **100**:2611-2621.

Rybalkin SD, Rybalkina I, Beavo JA and Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. *Circ Res* **90**:151-157.
Sabatini F, Petecchia L, Boero S, Silvestri M, Klar J, Tenor H, Beume R, Hatzelmann A and Rossi GA (2010) A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. *Pulm Pharmacol Ther* **23**:283-291.

Saber H, Desai A, Palla M, Mohamed W, Seraji-Bozorgzad N and Ibrahim M (2018) Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. *J Stroke Cerebrovasc Dis* **27**:2979-2985.

Sack LM, Davoli T, Li MZ, Li Y, Xu Q, Naxerova K, Wooten EC, Bernardi RJ, Martin TD, Chen T, Leng Y, Liang AC, Scorsone KA, Westbrook TF, Wong KK and Elledge SJ (2018) Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. *Cell* **173**:499-514 e423.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G and Hacohen N (2018) Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell* **175**:998-1013 e1020.

Sadek MS, Cachorro E, El-Armouche A and Kammerer S (2020) Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases. *Int J Mol Sci* **21**.

Sadiq MW, Holz O, Ellinghusen BD, Faulenbach C, Müller M, Badorrek P, Eriksson UG, Fridén M, Stomilovic S, Lundqvist AJ and Hohlfeld JM (2021) Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. *Br J Pharmacol* **178**:4440-4451.

Sakkas LI, Mavropoulos A and Bogdanos DP (2017) Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives. *Curr Med Chem* **24**:3054-3067.

Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H and Iwamoto T (2013) Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. *Geriatrics & gerontology international* **13**:90-97.

Salmon M, Tannheimer SL, Gentzler TT, Cui ZH, Sorensen EA, Hartsough KC, Kim M, Purvis LJ, Barrett EG, McDonald JD, Rudolph K, Doyle-Eisele M, Kuehl PJ, Royer CM, Baker WR, Phillips GB and Wright CD (2014) The *in vivo* efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β₂-adrenoceptor agonist in preclinical animal species. *Pharmacology research & perspectives* **2**:e00046.

Salpietro V, Perez-Duenas B, Nakashima K, San Antonio-Arce V, Manole A, Efthymiou S, Vandrovcova J, Bettencourt C, Mencacci NE, Klein C, Kelly MP, Davies CH, Kimura H, Macaya A and Houlden H (2018) A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea. *Movement disorders : official journal of the Movement Disorder Society* **33**:482-488.

Samidurai A, Xi L, Das A and Kukreja RC (2023) Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. *Annu Rev Pharmacol Toxicol* **63**:585-615.

Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M and Kitakaze M (2004) Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. *Circulation* **110**:51-57.

Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao YL, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T and Mori H (2001) Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors -The role of protein kinase A and p38 mitogen-activated protein kinase. *Circulation* **104**:705-710.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, lavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD,
Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research N, Van Allen EM, Cherniack AD, Ciriello G, Sander C and Schultz N (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell* **173**:321-337 e310.

Sano H, Nagai Y, Miyakawa T, Shigemoto R and Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. *Journal of neurochemistry* **105**:546-556.

Sanz MJ, Cortijo J, Taha MA, Cerda-Nicolas M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, Issekutz AC, Hatzelmann A and Morcillo EJ (2007) Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. *Br J Pharmacol* **152**:481-492.

Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet J-L, Delic J and Merle-Béral H (2003) Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. *Blood, The Journal of the American Society of Hematology* **101**:265-269.

Sarwar M, Sandberg S, Abrahamsson PA and Persson JL (2014) Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer. *Urol Oncol* **32**:25 e21-12.

Sasaki H, Hashimoto K, Inada T, Fukui S and Iyo M (1995) Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. *European journal of pharmacology* **282**:71-76.

Sasaki H, Nagayama T, Blanton RM, Seo K, Zhang M, Zhu G, Lee DI, Bedja D, Hsu S, Tsukamoto O, Takashima S, Kitakaze M, Mendelsohn ME, Karas RH, Kass DA and Takimoto E (2014) PDE5 inhibitor efficacy is estrogen dependent in female heart disease. *J Clin Invest* **124**:2464-2471.

Sasaki T, Kotera J and Omori K (2004) Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. *Journal of neurochemistry* **89**:474-483.

Savale L, Guignabert C, Weatherald J and Humbert M (2018) Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. *Eur Respir Rev* **27**.

Sayner SL, Alexeyev M, Dessauer CW and Stevens T (2006) Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. *Circ Res* **98**:675-681.

Sbornova I, van der Sande E, Milosavljevic S, Amurrio E, Burbano SD, Das P, Do H, Fisher JL, Kargbo P, Patel J, Porcher L, De Zeeuw CI, Meester-Smoor MA, Winkelman BHJ, Klaver CCW, Pocivavsek A and Kelly MP (2023) The sleep quality- and myopia-linked PDE11A-Y727C variant impacts neural physiology by reducing catalytic activity and altering subcellular compartmentalization of the enzyme. *bioRxiv*.

Schachter EN (2006) Cilomilast. *Drugs Today (Barc)* **42**:237-247.

Schafer PH, Adams M, Horan G, Truzzi F, Marconi A and Pincelli C (2019) Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice. *Drugs R D* **19**:329-338.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI and Chopra R (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal* **26**:2016-2029.

Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW and Stirling DI (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. *Br J Pharmacol* **159**:842-855.

Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A and Kreisel W (2018) Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in
experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. *World J Gastroenterol* **24**:4356-4368.

Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C and Walmrath D (1999) Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. *Am J Respir Crit Care Med* **160**:1500-1506.

Schermuly RT, Ghofrani HA, Wilkins MR and Grimminger F (2011) Mechanisms of disease: pulmonary arterial hypertension. *Nat Rev Cardiol* **8**:443-455.

Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D and Ghofrani HA (2001) Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. *Maintenance of lung selectivity. Am J Respir Crit Care Med* **164**:1694-1700.

Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W and Grimminger F (2007) Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation* **115**:2331-2339.

Schett G, Sloan VS, Stevens RM and Schafer P (2010) Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. *Therapeutic advances in musculoskeletal disease* **2**:271-278.

Schick MA and Schlegel N (2022) Clinical Implication of Phosphodiesterase-4-Inhibition. *Int J Mol Sci* **23**.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hammerling GJ, Schell TD, Garbi N and Greenberg PD (2016) Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. *Immunity* **45**:389-401.

Schioppa T, Nguyen HO, Salvi V, Maugeri N, Facchinetti F, Villetti G, Civelli M, Gaudenzi C, Passari M, Sozio F, Barbazza I, Tamassia N, Cassatella MA, Del Prete A, Bosisio D and Tiberio L (2022) The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils. *Int J Mol Sci* **23**.

Schippers M, Beljaars L, Post E, Lotersztajn S, Reker-Smit C, Han B, Munoz-Llancao P, Schmidt M and Poelstra K (2017) Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E(2) in Liver Fibrosis Is Associated with Reduced Fibrogenesis. *J Pharmacol Exp Ther* **363**:126-135.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD, 3rd, Williams RD, Verhoest PR and Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. *The Journal of pharmacology and experimental therapeutics* **325**:681-690.

Schmidt HH, Schmidt PM and Stasch JP (2009) NO- and haem-independent soluble guanylate cyclase activators. *Handb Exp Pharmacol*:309-339.

Schrag A and Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study. *Brain* **123**:2297-2305.

Schudt C, Tenor H and Hatzelmann A (1995) PDE isoenzymes as targets for anti-asthma drugs. *Eur Respir J* **8**:1179-1183.

Schultheiss D, Muller SV, Nager W, Stief CG, Schlote N, Jonas U, Asvestis C, Johannes S and Munte TF (2001) Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. *World journal of urology* **19**:46-50.

Schultz JE (2009) Structural and biochemical aspects of tandem GAF domains. *Handb Exp Pharmacol*:93-109.

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D and Altstiel LD (2014) A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. *Current Alzheimer research* **11**:413-421.
Scott JD, Dessauer CW and Tasken K (2013) Creating order from chaos: cellular regulation by kinase anchoring. *Annu Rev Pharmacol Toxicol* **53**:187-210.

Scott NJA, Prickett TCR, Charles CJ, Frampton CM, Richards AM and Rademaker MT (2023) Augmentation of Natriuretic Peptide Bioactivity via Combined Inhibition of Neprilysin and Phosphodiesterase-9 in Heart Failure. *JACC Heart Fail* **11**:227-239.

Scott NJA, Rademaker MT, Charles CJ, Espiner EA and Richards AM (2019) Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure. *J Am Coll Cardiol* **74**:889-901.

Sebastiani G, Morissette C, Lagace C, Boule M, Ouellette MJ, McLaughlin RW, Lacombe D, Gervais F and Tremblay P (2006) The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. *Neurobiol Aging* **27**:691-701.

Seimetz M, Parajuli N, Pichl A, Bednorz M, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F and Weissmann N (2015) Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. *PLoS One* **10**:e0129327.

Selige J, Hatzelmann A and Dunkern T (2011) The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. *J Cell Physiol* **226**:1970-1980.

Selige J, Tenor H, Hatzelmann A and Dunkern T (2010) Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. *J Cell Physiol* **223**:317-326.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V and Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *J Exp Med* **203**:2691-2702.

Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM and Giembycz MA (1998) Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. *J Biol Chem* **273**:20575-20588.

Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, Schutte H, Hippenstiel S and Suttorp N (2005) Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. *Blood* **105**:3569-3576.

Sgalla G, Ilovene B, Calvello M, Ori M, Varone F and Richeldi L (2018) Idiopathic pulmonary fibrosis: pathogenesis and management. *Respir Res* **19**:32.

Shan WJ, Huang L, Zhou Q, Jiang HL, Luo ZH, Lai KF and Li XS (2012a) Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. *Bioorg Med Chem Lett* **22**:1523-1526.

Shan X, Quaile MP, Monk JK, French B, Cappola TP and Margulies KB (2012b) Differential expression of PDE5 in failing and nonfailing human myocardium. *Circ Heart Fail* **5**:79-86.

Sharman SK, Islam BN, Hou Y, Singh N, Berger FG, Sridhar S, Yoo W and Browning DD (2018) Cyclic-GMP-Elevating Agents Suppress Polyposis in Apc(Min) mice by Targeting the Preneoplastic Epithelium. *Cancer Prev Res (Phila)* **11**:81-92.

Shekarian M, Komaki A, Shahidi S, Sarihi A, Salehi I and Raoufi S (2020) The protective and therapeutic effects of vinpocetine, a PDE1 inhibitor, on oxidative stress and learning and memory impairment induced by an intracerebroventricular (ICV) injection of amyloid beta (abeta) peptide. *Behavioural brain research* **383**:112512.

Shekarian M, Salehi I, Raoufi S, Asadbegi M, Kourosh-Arami M and Komaki A (2023) Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer's disease. *BMC neuroscience* **24**:20.

Shen Q, Cheng F, Song H, Lu W, Zhao J, An X, Liu M, Chen G, Zhao Z and Zhang J (2017) Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7,000 cancer genomes. *The American Journal of Human Genetics* **100**:5-20.
Shepherd MC, Baillie GS, Stirling DI and Houslay MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. *Br J Pharmacol* **142**:339-351.

Sheth SB, Chaganti K, Bastepe M, Ajuria J, Brennan K, Biradavolu R and Colman RW (1997) Cyclic AMP phosphodiesterases in human lymphocytes. *Br J Haematol* **99**:784-789.

Shi J, Li Y, Zhang Y, Chen J, Gao J, Zhang T, Shang X and Zhang X (2021a) Baicalein Ameliorates Abeta-Induced Memory Deficits and Neuronal Atrophy via Inhibition of PDE2 and PDE4. *Frontiers in pharmacology* **12**:794458.

Shi Y, Lv J, Chen L, Luo G, Tao M, Pan J, Hu X, Sheng J, Zhang S, Zhou M and Fan H (2021b) Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer's Disease. *Frontiers in aging neuroscience* **13**:722580.

Shimizu-Albergine M, Van Yserloo B, Golkowski MG, Ong SE, Beavo JA and Bornfeldt KE (2016) SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP. *Proc Natl Acad Sci U S A* **113**:E5685-5693.

Shimoda LA (2020) Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia. *Physiology (Bethesda)* **35**:222-233.

Shimoda LA and Laurie SS (2013) Vascular remodeling in pulmonary hypertension. *J Mol Med (Berl)* **91**:297-309.

Shirayama Y, Konishi T and Hashimoto K (2011) Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial. *Journal of clinical psychopharmacology* **31**:659-661.

Shonberg J, Scammells PJ and Capuano B (2011) Design strategies for bivalent ligands targeting GPCRs. *ChemMedChem* **6**:963-974.

Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA and Davis DMR (2023) Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am Acad Dermatol* **89**:e1-e20.

Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE and Held W (2019) Intratumoral Tcf1(+)-PD-1(+)-CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* **50**:195-211 e110.

Singh D (2023) A New Treatment for Chronic Obstructive Pulmonary Disease: Ensifentrine Moves Closer. *Am J Respir Crit Care Med* **208**:344-346.

Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M and Nandeuil MA (2019) Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. *Respir Res* **20**:180.

Singh D, Emirova A, Francisco C, Santoro D, Govoni M and Nandeuil MA (2020a) Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. *Respir Res* **21**:246.

Singh D, Martinez FJ, Watz H, Bengtsson T and Maurer BT (2020b) A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. *Respir Res* **21**:47.

Singh SP, Mishra NC, Rir-Sima-Ah J, Campen M, Kurup V, Razani-Boroujerdi S and Sopori ML (2009) Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and atopy. *J Immunol* **183**:2115-2121.

Sisson TH, Christensen PJ, Muraki Y, Dils AJ, Chibucos L, Subbotina N, Tohyama K, Horowitz JC, Matsuo T, Bailie M, Nikam S and Hazama M (2018) Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. *Physiol Rep* **6**:e13753.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. *Neuropharmacology* **51**:386-396.
Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS and Schmidt CJ (2006b) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. *Neuropharmacology* **51**:386-396.

Siuciak JA, Chapin DS, McCarthy SA and Martin AN (2007a) Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. *Psychopharmacology* **192**:415-424.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS and Schmidt CJ (2006c) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. *Neuropharmacology* **51**:374-385.

Siuciak JA, McCarthy SA, Chapin DS and Martin AN (2008a) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. *Psychopharmacology* **197**:115-126.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF and Schmidt CJ (2008b) Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. *Neuropharmacology* **54**:417-427.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV and Repaske DR (2007b) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. *Neuropharmacology* **53**:113-124.

Skryabin EB, De Jong KA, Subramanian H, Bork NI, Froese A, Skryabin BV and Nikolaev VO (2023) CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms. *Cells* **12**.

Smart L, Gobejishvili L, Crittenden N, Barve S and McClain CJ (2013) Alcoholic Hepatitis: Steroids vs. Pentoxifylline. *Curr Hepat Rep* **12**:59-65.

Smith AJ, Farmer R, Pilarzyk K, Porcher L and Kelly MP (2021) A genetic basis for friendship? Homophily for membrane-associated PDE11A-cAMP-CREB signaling in CA1 of hippocampus dictates mutual social preference in male and female mice. *Molecular psychiatry* **26**:7107-7117.

Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS and Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. *Am J Physiol Lung Cell Mol Physiol* **284**:L279-289.

Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS and Giembycz MA (2004a) Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. *Molecular pharmacology* **66**:1679-1689.

Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS and Giembycz MA (2004b) Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. *Mol Pharmacol* **66**:1679-1689.

Snyder GL, Prickaerts J, Wadenberg M-L, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP and Vanover KE (2016a) Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. *Psychopharmacology* **233**:3113-3124.

Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S and Wennogle LP (2016b) Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. *Psychopharmacology (Berl)* **233**:3113-3124.

Soderling SH, Bayuga SJ and Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. *Proc Natl Acad Sci U S A* **95**:8991-8996.

Sommer N, Martin R, McFarland HF, Quigley L, Cannella B, Raine CS, Scott DE, Loschmann PA and Racke MK (1997) Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. *J Neuroimmunol* **79**:54-61.
Sonnenburg WK, Mullaney PJ and Beavo JA (1991) Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. *J Biol Chem* **266**:17655-17661.

Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn Jr PA and Chou T-C (1999) Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. *Cancer Research* **59**:6178-6184.

Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP and Vlachopoulos C (2024) Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother* **10**:403-412.

Spagnolo P, Tzouvelekis A and Bonella F (2018) The Management of Patients With Idiopathic Pulmonary Fibrosis. *Front Med (Lausanne)* **5**:148.

Spiranec K, Chen W, Werner F, Nikolaev VO, Naruke T, Koch F, Werner A, Eder-Negrin P, Dieguez-Hurtado R, Adams RH, Baba HA, Schmidt H, Schuh K, Skryabin BV, Movahedi K, Schweda F and Kuhn M (2018) Endothelial C-Type Natriuretic Peptide Acts on Pericytes to Regulate Microcirculatory Flow and Blood Pressure. *Circulation* **138**:494-508.

Spranger S, Bao R and Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature* **523**:231-235.

Spranger S, Dai D, Horton B and Gajewski TF (2017) Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. *Cancer Cell* **31**:711-723 e714.

Spranger S and Gajewski TF (2015) A new paradigm for tumor immune escape: beta-catenin-driven immune exclusion. *J Immunother Cancer* **3**:43.

Sprenger JU, Perera RK, Steinbrecher JH, Lehnart SE, Maier LS, Hasenfuss G and Nikolaev VO (2015) In vivo model with targeted cAMP biosensor reveals changes in receptor-microdomain communication in cardiac disease. *Nat Commun* **6**:6965.

Sridharan K, Sivaramakrishnan G, Sequeira RP and Elamin A (2018) Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. *Postgrad Med J* **94**:556-565.

Sriram K and Insel PA (2018) G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? *Mol Pharmacol* **93**:251-258.

Stancheva SL and Alova LG (1991) Age-related changes of cyclic AMP phosphodiesterase activity in rat brain regions and a new phosphodiesterase inhibitor--nootropic agent adafenoxate. *General pharmacology* **22**:955-958.

Steinfeld T, Hughes AD, Klein U, Smith JA and Mammen M (2011) THRX-198321 is a bifunctional muscarinic receptor antagonist and β₂-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. *Molecular Pharmacology* **79**:389-399.

Steinman L (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. *Nat Rev Drug Discov* **4**:510-518.

Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P and van Stolk RU (1999) Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. *Adv Exp Med Biol* **470**:45-53.

Subhan Z and Hindmarch I (1985) Psychopharmacological effects of vinpocetine in normal healthy volunteers. *European journal of clinical pharmacology* **28**:567-571.

Subramaniam G, Schleicher K, Kovanich D, Zerio A, Folkmanaite M, Chao YC, Surdo NC, Koschinski A, Hu J, Scholten A, Heck AJR, Ercu M, Sholokh A, Park KC, Klussmann E, Meraviglia V, Bellin M, Zanivan S, Hester S, Mohammed S and Zaccolo M (2023) Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy. *Circ Res* **132**:828-848.

Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y and Hidaka H (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. *Biochem Pharmacol* **59**:347-356.
Sumimoto H, Takano A, Teramoto K and Daigo Y (2016) RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. *PLoS One* **11:e0166626.**

Surapisitchat J, Jeon KI, Yan C and Beavo JA (2007) Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. *Circ Res* **101**:811-818.

Surdo NC, Berrera M, Koschinski A, Brescia M, Machado MR, Carr C, Wright P, Gorelik J, Morotti S, Grandi E, Bers DM, Pantano S and Zaccolo M (2017) FRET biosensor uncovers cAMP nano-domains at beta-adrenergic targets that dictate precise tuning of cardiac contractility. *Nat Commun* **8**:15031.

Suryawanshi A and Manicassamy S (2015) Tumors induce immune tolerance through activation of beta-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy. *Oncoimmunology* **4:e1052932.**

Susuki-Miyata S, Miyata M, Lee BC, Xu H, Kai H, Yan C and Li JD (2015) Cross-talk between PKA-Cbeta and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi. *Proc Natl Acad Sci U S A* **112**:E1800-1809.

Sutherland EW (1972) Studies on the mechanism of hormone action. *Science* **177**:401-408.

Sutherland EW and Rall TW (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J Biol Chem* **232**:1077-1091.

Sutherland EW and Rall TW (1960) Formation of adenosine-3,5-phosphate (cyclic adenylate) and its relation to the action of several neurohormones or hormones. *Acta Endocrinol Suppl (Copenh)* **34(Suppl 50)**:171-174.

Suzuki O, Mizukami K, Etori M, Sogawa Y, Takagi N, Tsuchida H, Morimoto K, Goto T, Yoshino T, Mikkaichi T, Hirahara K, Nakamura S and Maeda H (2013) Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice. *J Pharmacol Sci* **123**:219-226.

Swetha R, Sharma A, Singh R, Ganeshpurkar A, Kumar D, Kumar A and Singh SK (2022) Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer's disease. *Mol Divers* **26**:2877-2892.

Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Kroll-Desrosiers A, Tornai D, Min HA, Radaeva S, Holbein MEB, Casey L and Cuthbert J (2022) IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. *Hepatology* **76**:1058-1068.

Szatmari SZ and Whitehouse PJ (2003) Vinpocetine for cognitive impairment and dementia. *The Cochrane database of systematic reviews*:CD003119.

Szczypka M (2020) Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions. *Int J Mol Sci* **21**.

Tabrizian K, Amelinia F, Belaran M, Pourheidar S, Mirzaei H and Fanoudi S (2021) Tadalafil Reversed H-89 - and Scopolamine - Induced Spatial Learning Impairments in Male Rats. *Drug research* **71**:275-283.

Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, Nishino M, Stern D and Okada M (2013) Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. *Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society* **13**:164-169.

Tai SY, Chen CH, Chien CY and Yang YH (2017a) Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study. *BMC neurology* **17**:40.

Tai SY, Chien CY, Chang YH and Yang YH (2017b) Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* **14**:784-791.

Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M and Duman RS (1999a) Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. *J Neurosci* **19**:610-618.

Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M and Duman RS (1999b) Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. *Journal of Neuroscience* **19**:610-618.
Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ and Kass DA (2005) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. *Circ Res* **96**:100-109.

Takimoto E, Koitabashi N, Hsu S, Ketner EA, Nagayama T, Bedja D, Gabrielson K, Blanton R, Siderovski DP, Mendelsohn ME and Kass DA (2009) RGS2 mediates cardiac compensation to pressure-overload and anti-hypertrophic effects of PDE5 inhibition. *J Clin Invest* **119**:408-420.

Tang H, Vanderpool RR, Wang J and Yuan JX (2017) Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension. *Pulm Circ* **7**:569-571.

Tannheimer SL, Sorensen EA, Cui ZH, Kim M, Patel L, Baker WR, Phillips GB, Wright CD and Salmon M (2014) The *in vitro* pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β₂-adrenoceptor agonist. *Journal of Pharmacology and Experimental Therapeutics* **349**:85-93.

Tannheimer SL, Wright CD and Salmon M (2012) Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. *Respir Res* **13**:28.

Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE and Joers V (2022) Inflammation and immune dysfunction in Parkinson disease. *Nature Reviews Immunology* **22**:657-673.

Tao AJ, Gadbois GE, Buczynski SA and Ferguson FM (2022a) Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. *Curr Opin Chem Biol* **67**:102114.

Tao X, Chen C, Huang Z, Lei Y, Wang M, Wang S and Tian D (2023) Genetic deletion of phosphodiesterase 4D in the liver improves kidney damage in high-fat fed mice: liver-kidney crosstalk. *Cell Death Dis* **14**:273.

Tao X, He H, Peng J, Xu R, Fu J, Hu Y, Li L, Yang X, Feng X, Zhang C, Zhang L, Yu X, Shen A, Huang K and Fu Q (2022b) Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-beta1 pathway: therapeutic role of roflumilast. *Pharmacol Res* **175**:106004.

Tao Y, Gu YJ, Cao ZH, Bian XJ, Lan T, Sang JR, Jiang L, Wang Y, Qian H and Chen YC (2012) Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239. *Oncol Lett* **4**:1104-1108.

Taylor IK, O'Shaughnessy KM, Fuller RW and Dollery CT (1991) Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. *Lancet* **337**:690-694.

Taylor JL, Bishop C and Walker PD (2005) Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. *Pharmacology Biochemistry and Behavior* **81**:887-893.

Taylor KE, Wong Q, Levine DM, McHugh C, Laurie C, Doheny K, Lam MY, Baer AN, Challacombe S, Lanfranchi H, Schiodt M, Srinivasan M, Umehara H, Vivino FB, Zhao Y, Shiboski SC, Daniels TE, Greenspan JS, Shiboski CH and Criswell LA (2017) Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjogren's Syndrome According to Ancestry. *Arthritis Rheumatol* **69**:1294-1305.

Teixeira CE, Priviero FB and Webb RC (2006) Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. *J Pharmacol Exp Ther* **316**:654-661.

Tejeda GS, Whiteley EL, Deeb TZ, Burli RW, Moss SJ, Sheridan E, Brandon NJ and Baillie GS (2020) Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme. *Proceedings of the National Academy of Sciences of the United States of America* **117**:677-688.

Tello K, Naeije R, de Man F and Guazzi M (2023) Pathophysiology of the right ventricle in health and disease: an update. *Cardiovasc Res* **119**:1891-1904.

Teng M, Lu W, Donovan KA, Sun J, Krupnick NM, Nowak RP, Li YD, Sperling AS, Zhang T, Ebert BL, Fischer ES and Gray NS (2022) Development of PDE6D and CK1alpha Degraders through Chemical Derivatization of FPFT-2216. *J Med Chem* **65**:747-756.
Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K and Bethke TD (2011) Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. *Handb Exp Pharmacol* :85-119.

Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, Wendel A, Church MK and Shute JK (1995a) Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. *Clin Exp Allergy* **25**:625-633.

Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanovic R, Church MK and Shute JK (1995b) Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. *Clin Exp Allergy* **25**:616-624.

Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ and van Honk J (2013) Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* **38**:2708-2716.

Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, Lynch MJ, Elvassore N, Prinz A, Herberg FW, Houslay MD and Zaccolo M (2006) PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. *J Cell Biol* **175**:441-451.

Teschke R (2018) Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. *Expert Opin Pharmacother* **19**:779-793.

Thal LJ, Salmon DP, Lasker B, Bower D and Klauber MR (1989) The safety and lack of efficacy of vinpocetine in Alzheimer's disease. *Journal of the American Geriatrics Society* **37**:515-520.

Thelitz S, Oishi P, Sanchez LS, Bekker JM, Ovadia B, Johengen MJ, Black SM and Fineman JR (2004) Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. *Pediatr Crit Care Med* **5**:234-239.

Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R and Ahnen DJ (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. *Cancer Res* **57**:267-271.

Thompson WJ and Appleman MM (1971) Multiple cyclic nucleotide phosphodiesterase activities from rat brain. *Biochemistry* **10**:311-316.

Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R (2000) Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. *Cancer Res* **60**:3338-3342.

Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH and Trial S (2015) Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* **372**:1619-1628.

Tian X, Vroom C, Ghofrani HA, Weissmann N, Bieniek E, Grimminger F, Seeger W, Schermuly RT and Pullamsetti SS (2011) Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. *PLoS One* **6**:e18136.

Tibbo AJ, Mika D, Dobi S, Ling J, McFall A, Tejeda GS, Blair C, MacLeod R, MacQuaide N, Gok C, Fuller W, Smith BO, Smith GL, Vandecasteele G, Brand T and Baillie GS (2022) Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. *J Mol Cell Cardiol* **165**:86-102.

Tilley DG and Maurice DH (2002) Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. *Mol Pharmacol* **62**:497-506.

Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y and Piazza GA (2011) Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. *Cancer Prev Res (Phila)* **4**:1275-1284.

Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC and Piazza GA (2009) Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. *Molecular cancer therapeutics* **8**:3331-3340.